<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:advb="http://advanbiomed.com/20260630"
  xmlns:country="http://xbrl.sec.gov/country/2026"
  xmlns:currency="http://xbrl.sec.gov/currency/2026"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2026"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="advb-20260630.xsd" xlink:type="simple"/>
    <context id="cref_1268430831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_518000893">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1292941150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1380723918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1127853967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1766841203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:MrJieWangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1226777713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:RelatedCorporationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_554179130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:RelatedCorporationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1973210640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:RelatedCorporationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_481337955">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:RelatedCorporationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1398217206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:MajorStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1519822248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:MajorStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:JieWangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1784635127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:MajorStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:XiaominChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1555499812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1035987879">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:JieWangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_347602649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:HungToPauPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_2097405023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:XiaominChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1493501123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advb:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1042470024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advb:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1071870216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_372109222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_2033103817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:TW</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_305121392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_607253543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1670724461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1373556371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_708356424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_695989797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1096537008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_615613204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1556537373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1684648503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">advb:SharesIssuedForAcquisitionOfAcellentAndStockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_753226158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">advb:SharesIssuedForAcquisitionOfAcellentAndStockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_400658640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">advb:SharesIssuedForAcquisitionOfAcellentAndStockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_881634151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">advb:FractionalShareAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="cref_1720826237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">advb:FractionalShareAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="cref_332577736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">advb:SharesIssuedForCommitmentFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_2117020605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">advb:SharesIssuedForCommitmentFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_999016331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">advb:SharesIssuedForCommitmentFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1796841557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_805845135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_776183407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_838649397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-07</startDate>
            <endDate>2025-03-07</endDate>
        </period>
    </context>
    <context id="cref_1925713941">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-07</startDate>
            <endDate>2025-03-07</endDate>
        </period>
    </context>
    <context id="cref_1427765276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-07</instant>
        </period>
    </context>
    <context id="cref_1367130439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-20</startDate>
            <endDate>2026-02-20</endDate>
        </period>
    </context>
    <context id="cref_629018526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-15</startDate>
            <endDate>2024-10-15</endDate>
        </period>
    </context>
    <context id="cref_651681905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:FormerSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_98957588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_934092959">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:AdvancedBiomedHKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1161182051">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:AdvancedBiomedIncTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_809252632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">advb:TaiwanSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_2137941047">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">advb:HongKongSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1234264462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_944234346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">advb:TaiwanSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_890578433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">advb:HongKongSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2109378812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">advb:HongKongSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1622985829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <startDate>2026-06-30</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_677513081">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <startDate>2025-12-23</startDate>
            <endDate>2025-12-23</endDate>
        </period>
    </context>
    <context id="cref_1733049814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:AcellentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_512039560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:AcellentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-02</startDate>
            <endDate>2026-04-02</endDate>
        </period>
    </context>
    <context id="cref_1539055106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:AcellentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-02</instant>
        </period>
    </context>
    <context id="cref_518123335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:AcellentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-02</instant>
        </period>
    </context>
    <context id="cref_343760561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:AcellentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-02</startDate>
            <endDate>2026-04-02</endDate>
        </period>
    </context>
    <context id="cref_811874486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:AcellentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">advb:SaleAndPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-02</instant>
        </period>
    </context>
    <context id="cref_66595141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-20</startDate>
            <endDate>2026-02-20</endDate>
        </period>
    </context>
    <context id="cref_227132498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1606981235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1632848432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_270933567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_829090450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2121645178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:TWD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1616045213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:TWD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1974873320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:TWD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1798085713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:TWD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1619078810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-28</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="cref_522535513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="cref_1877900993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_372193311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_951683079">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedHKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_23459831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedHKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1189438897">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedIncTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_492101464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedIncTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_378644450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AcellentTechnologiesHongKongCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_892504388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_91010303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-03</startDate>
            <endDate>2026-02-03</endDate>
        </period>
    </context>
    <context id="cref_1379153066">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">advb:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="cref_2137289145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advb:JanuaryTwoThousandTwentySixPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-20</startDate>
            <endDate>2026-02-20</endDate>
        </period>
    </context>
    <context id="cref_1880182860">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advb:JanuaryTwoThousandTwentySixPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="cref_387884904">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advb:JanuaryTwoThousandTwentySixPrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="cref_1907271931">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:AcellentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="cref_185613871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:AcellentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="cref_1904813312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_554751373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-23</instant>
        </period>
    </context>
    <context id="cref_906810478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-23</startDate>
            <endDate>2025-12-23</endDate>
        </period>
    </context>
    <context id="cref_1440922954">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1044073967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1622799614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1527988905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1515466520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_471026296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1756868353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_940316359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_327918837">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_969532781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_207845589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1755322658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_71328825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_770078133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_488074029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1184248197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_871642115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_2016794188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1559650067">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_958460008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1066705290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <instant>2026-10-13</instant>
        </period>
    </context>
    <context id="cref_1494957061">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1527746651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advb:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_2017348691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_748908903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:MajorStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:XiaominChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_562830761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:MajorStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:JieWangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1384483165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:MajorStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_335351225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">advb:TaiwanSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1263417979">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AcellentTechnologiesHongKongCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_289217852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1089681296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_519963710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1539137384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1568172215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:TW</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_717167906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <unit id="uref_518000893">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="uref_205481031">
        <measure>iso4217:HKD</measure>
    </unit>
    <unit id="uref_345177085">
        <measure>advb:Segments</measure>
    </unit>
    <unit id="uref_1766841203">
        <measure>pure</measure>
    </unit>
    <unit id="uref_1493501123">
        <measure>shares</measure>
    </unit>
    <unit id="uref_1427765276">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="cref_1096537008"
      id="fc_2062229985"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:DueFromDiscontinuedOperations
      contextRef="cref_1380723918"
      id="fc_1979548981"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="cref_1380723918"
      id="fc_763204837"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="cref_1380723918"
      id="fc_1826879828"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="cref_1380723918"
      id="fc_939357978"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="cref_1494957061"
      id="fc_1494957061"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="cref_1268430831" id="ixv-10769">0001941029</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="cref_1268430831" id="ixv-10770">false</dei:AmendmentFlag>
    <dei:EntityAddressPostalZipCode contextRef="cref_1268430831" id="ixv-10771">00000</dei:EntityAddressPostalZipCode>
    <dei:DocumentFiscalPeriodFocus contextRef="cref_1268430831" id="ixv-10772">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="cref_1380723918"
      id="fc_346673626"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="cref_1380723918"
      id="fc_786825685"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="cref_1527746651"
      id="fc_1527746651"
      unitRef="uref_1493501123"
      xsi:nil="true"/>
    <advb:OtherItemsFromContinuingOperations
      contextRef="cref_1127853967"
      id="fc_1535481324"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="cref_1096537008"
      id="fc_1216296237"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="cref_1380723918"
      id="fc_430576420"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="cref_1096537008"
      id="fc_1401415844"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_471026296"
      id="fc_1840138848"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_1756868353"
      id="fc_1092735888"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_1268430831"
      id="fc_913398623"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_471026296"
      id="fc_1392405915"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_1756868353"
      id="fc_1787180234"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_805845135"
      id="fc_589906515"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_471026296"
      id="fc_310234921"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1756868353"
      id="fc_765289002"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="cref_1127853967"
      id="fc_11501882"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="cref_1127853967"
      id="fc_1671467595"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="cref_1127853967"
      id="fc_1420834850"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_1127853967"
      id="fc_1527865755"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:AmountDueFromFormerSubsidiaries
      contextRef="cref_1096537008"
      id="fc_1368213769"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:Supplies
      contextRef="cref_1096537008"
      id="fc_1871852015"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:AllowanceForExpectedCreditLosses
      contextRef="cref_1096537008"
      id="fc_865206575"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:AllowanceForExpectedCreditLosses
      contextRef="cref_1440922954"
      id="fc_1993217282"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:ProvisionForAllowanceForExpectedCreditLosses
      contextRef="cref_1127853967"
      id="fc_708193469"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:AllowanceForExpectedCreditLossesWriteoff
      contextRef="cref_1127853967"
      id="fc_1390680715"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:AllowanceForExpectedCreditLosses
      contextRef="cref_1096537008"
      id="fc_1426344310"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:PrepaymentCurrent
      contextRef="cref_1380723918"
      id="fc_965959833"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="cref_1096537008"
      id="fc_521368573"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent
      contextRef="cref_1096537008"
      id="fc_1375650588"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:CommonStockIssuedForCommitmentFee
      contextRef="cref_1127853967"
      id="fc_711942418"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_1127853967"
      id="fc_460500971"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="cref_1127853967"
      id="fc_316968503"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="cref_1127853967"
      id="fc_689418395"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="cref_1127853967"
      id="fc_1945163155"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="cref_1127853967"
      id="fc_926620208"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_1127853967"
      id="fc_399702206"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="cref_1127853967"
      id="fc_1826400270"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:CommonStockIssuedInSettlementOfCommitmentFees
      contextRef="cref_1127853967"
      id="fc_1850763379"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:CommonStockIssuedForAcquisitionOfAcellent
      contextRef="cref_1127853967"
      id="fc_2141684343"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:StockBasedCompensation
      contextRef="cref_1127853967"
      id="fc_1447090972"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="cref_1127853967"
      id="fc_1330587441"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1127853967"
      id="fc_1085086913"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="cref_892504388"
      id="fc_2069444419"
      unitRef="uref_1766841203"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="cref_2017348691"
      id="fc_2017348691"
      unitRef="uref_1766841203"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="cref_1189438897"
      id="fc_1497991597"
      unitRef="uref_1766841203"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="cref_1380723918"
      id="fc_1271090401"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="cref_1380723918"
      id="fc_1711824719"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="cref_481337955"
      id="fc_78357966"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="cref_1973210640"
      id="fc_92680800"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilities
      contextRef="cref_748908903"
      id="fc_748908903"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilities
      contextRef="cref_562830761"
      id="fc_562830761"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilities
      contextRef="cref_1384483165"
      id="fc_1384483165"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="cref_1268430831"
      id="fc_516370733"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="cref_1127853967"
      id="fc_91068169"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="cref_1380723918"
      id="fc_1606802807"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="cref_1380723918"
      id="fc_309314987"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="cref_1380723918"
      id="fc_1181372779"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="cref_1380723918"
      id="fc_1105684479"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:DisposalGroupIncludingDiscontinuedOperationRightofuseAssetsNet
      contextRef="cref_1380723918"
      id="fc_1908456561"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="cref_1380723918"
      id="fc_1108096154"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="cref_1380723918"
      id="fc_1140262525"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="cref_1380723918"
      id="fc_1488126211"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="cref_1380723918"
      id="fc_731755198"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:DisposalGroupIncludingDiscontinuedOperationLiabilitiesAmountDueToTheCompanyCurrent
      contextRef="cref_1380723918"
      id="fc_939041857"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="cref_1380723918"
      id="fc_1387464487"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:DisposalGroupIncludingDiscontinuedOperationLiabilitiesNoncurrentAmountDuetoRelatedPartiesNonCurrent
      contextRef="cref_1380723918"
      id="fc_1349873447"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="cref_1380723918"
      id="fc_220337250"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="cref_1268430831"
      id="fc_1778345013"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="cref_1127853967"
      id="fc_53216848"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="cref_1127853967"
      id="fc_1785573186"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="cref_1380723918"
      id="fc_2120331561"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="cref_1234264462"
      id="fc_1695365751"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets
      contextRef="cref_1380723918"
      id="fc_1804957200"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:DisposalGroupIncludingDiscontinuedOperationLeaseLiabilities
      contextRef="cref_1234264462"
      id="fc_1282026241"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:DisposalGroupIncludingDiscontinuedOperationDueToRelatedParties
      contextRef="cref_890578433"
      id="fc_2142985455"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:DisposalGroupIncludingDiscontinuedOperationDueToTheCompany
      contextRef="cref_2109378812"
      id="fc_338277775"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:DisposalGroupIncludingDiscontinuedOperationDueToRelatedParties
      contextRef="cref_335351225"
      id="fc_335351225"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxPayable
      contextRef="cref_1380723918"
      id="fc_948391774"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:DiscontinuedOperationNetCashInflowOutflowArisingFromCashConsiderationReceived
      contextRef="cref_809252632"
      id="fc_189817666"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="cref_1226777713"
      id="fc_709321675"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="cref_554179130"
      id="fc_1006299734"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="cref_1263417979"
      id="fc_1263417979"
      unitRef="uref_1766841203"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="cref_951683079"
      id="fc_1454131596"
      unitRef="uref_1766841203"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="cref_1877900993"
      id="fc_936064758"
      unitRef="uref_1766841203"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_289217852"
      id="fc_289217852"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_1127853967"
      id="fc_64957701"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OperatingLossCarryforwards
      contextRef="cref_1089681296"
      id="fc_1089681296"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OperatingLossCarryforwards
      contextRef="cref_519963710"
      id="fc_519963710"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OperatingLossCarryforwards
      contextRef="cref_1539137384"
      id="fc_1539137384"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="cref_1096537008"
      id="fc_1825277270"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:DeferredTaxAssetsAllowanceForExpectedCreditLosses
      contextRef="cref_1096537008"
      id="fc_1798789769"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="cref_1268430831"
      id="fc_533274868"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="cref_1127853967"
      id="fc_519175881"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="cref_1127853967"
      id="fc_1377035759"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="cref_1127853967"
      id="fc_99184308"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="cref_1268430831"
      id="fc_995735450"
      unitRef="uref_1766841203"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="cref_1127853967"
      id="fc_558512107"
      unitRef="uref_1766841203"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="cref_1127853967"
      id="fc_1323830959"
      unitRef="uref_1766841203"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="cref_1127853967"
      id="fc_1459257994"
      unitRef="uref_1766841203"
      xsi:nil="true"/>
    <us-gaap:OperatingLossCarryforwards
      contextRef="cref_1568172215"
      id="fc_1568172215"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OperatingLossCarryforwards
      contextRef="cref_717167906"
      id="fc_717167906"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <dei:CurrentFiscalYearEndDate contextRef="cref_1268430831" id="fc_1864160348">--06-30</dei:CurrentFiscalYearEndDate>
    <us-gaap:Revenues
      contextRef="cref_1127853967"
      id="fc_1067729861"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_1127853967"
      id="fc_1668669101"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_770078133"
      id="fc_1081343444"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_71328825"
      id="fc_628131206"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1755322658"
      id="fc_1652478117"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1755322658"
      id="fc_177806499"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration contextRef="cref_1268430831" id="fc_993672847">http://fasb.org/srt/2026#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_488074029"
      id="fc_699435574"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="cref_770078133"
      id="fc_1956081101"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="cref_71328825"
      id="fc_1420963489"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="cref_488074029"
      id="fc_1975438422"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_805845135"
      id="fc_1242503141"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1796841557"
      id="fc_387718152"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_471026296"
      id="fc_1354936998"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:StockIssuedDuringPeriodValuePrivatePlacement
      contextRef="cref_471026296"
      id="fc_1477055197"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <advb:StockIssuedDuringPeriodValuePrivatePlacement
      contextRef="cref_1756868353"
      id="fc_1598441347"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_471026296"
      id="fc_73370363"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_1756868353"
      id="fc_1997578892"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="cref_805845135"
      id="fc_1749169838"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="cref_1796841557"
      id="fc_277234472"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="cref_1756868353"
      id="fc_785052473"
      unitRef="uref_518000893"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="cref_1268430831" id="ixv-11910">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="cref_1268430831" id="fc_1262744147">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="cref_1268430831" id="ixv-28">2026-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="cref_1268430831" id="ixv-11912">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="cref_1268430831" id="ixv-11913">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="cref_1268430831" id="ixv-11914">001-42548</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="cref_1268430831" id="ixv-11915">Advanced Biomed Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="cref_1268430831" id="ixv-11916">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="cref_1268430831" id="ixv-11917">87-2177170</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="cref_1268430831" id="ixv-67">Units No. 12, 12th Floor, Tower 1</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="cref_1268430831" id="ixv-11918">W MEGA</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="cref_1268430831" id="ixv-11919">Non. 252 Texaco Road and No. 28 Wang Lung Street, Tsuen Wan</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="cref_1268430831" id="fc_1517077187">New Territories</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="cref_1268430831" id="ixv-11921">HK</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="cref_1268430831" id="ixv-11922">852</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="cref_1268430831" id="ixv-11923">31580999</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="cref_1268430831" id="ixv-11924">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="cref_1268430831" id="ixv-11925">ADVB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="cref_1268430831" id="ixv-11926">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="cref_1268430831" id="ixv-11927">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="cref_1268430831" id="ixv-11928">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="cref_1268430831" id="ixv-11929">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="cref_1268430831" id="ixv-11930">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="cref_1268430831" id="ixv-11931">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="cref_1268430831" id="ixv-11932">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="cref_1268430831" id="ixv-11933">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="cref_1268430831" id="ixv-11934">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="cref_1268430831" id="ixv-11935">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="cref_1268430831" id="ixv-11936">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="cref_1268430831" id="ixv-11937">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="cref_1234264462"
      decimals="-5"
      id="ixv-11938"
      unitRef="uref_518000893">2700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="cref_1066705290"
      decimals="0"
      id="ixv-11939"
      unitRef="uref_1493501123">1652133</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="cref_1268430831" id="ixv-11940">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="cref_1268430831" id="ixv-1999">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"&gt;We recognize the importance of identifying, assessing, and managing material risks from cybersecurity threats, as defined in Item 106(a) of Regulation S-K. Our risk management program is designed to detect, evaluate, and mitigate cybersecurity risks, and is informed by applicable laws, regulations, and industry best practices.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"&gt;Our Chief Executive Officer oversees our cybersecurity program and leads our incident response efforts. The incident response team is cross-functional, drawing members from cybersecurity, IT support, software engineering, compliance, legal, contractors, and partners.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"&gt;When a potential incident is detected, the cybersecurity team validates it before escalating to the incident response team for triage. Significant incidents are escalated to executive management. Response actions such as allocating resources, setting priorities, creating action plans, and notifying external parties are directed by the Chief Executive Officer in coordination with the cross-functional working group. We also consult outside counsel on materiality assessments and disclosure decisions, with executive management making the final determinations.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"&gt; During the fiscal year ended June 30, 2026, we did not identify any cybersecurity threats that materially affected, or are reasonably likely to materially affect, our strategy, operations, or financial condition. However, no program can eliminate all risks, and we cannot guarantee that undetected incidents have not occurred. See Part I, Item 1A. &#x201c;Risk Factors&#x201d; of this Annual Report for further details. &lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="cref_1268430831" id="ixv-2002">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"&gt;Our Chief Executive Officer oversees our cybersecurity program and leads our incident response efforts. The incident response team is cross-functional, drawing members from cybersecurity, IT support, software engineering, compliance, legal, contractors, and partners.&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="cref_1268430831" id="ixv-11941">The incident response team is cross-functional, drawing members from cybersecurity, IT support, software engineering, compliance, legal, contractors, and partners.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="cref_1268430831" id="ixv-11942">During the fiscal year ended June 30, 2026, we did not identify any cybersecurity threats that materially affected, or are reasonably likely to materially affect, our strategy, operations, or financial condition.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="cref_1268430831" id="ixv-11943">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="cref_1268430831" id="ixv-11944">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="cref_1268430831" id="ixv-11945">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="cref_1268430831" id="ixv-11946">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="cref_1268430831" id="ixv-11947">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="cref_1268430831" id="ixv-11948">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorOpinionTextBlock contextRef="cref_1268430831" id="ixv-4667">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;We have audited the accompanying consolidated balance sheets of Advanced Biomed Inc. and its subsidiaries (collectively, the &#x201c;Company&#x201d;) as of June 30, 2026 and 2025, and the related consolidated statements of operations and comprehensive income (loss), changes in stockholders&#x2019; equity, and cash flows for each of the years in the two-year period ended June 30, 2026, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2026 and 2025, and the results of its operations and its cash flows for each of the years in the two-year period ended June 30, 2026, in conformity with accounting principles generally accepted in the United States of America.&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="cref_1268430831" id="ixv-11949">WWC, P.C.</dei:AuditorName>
    <dei:AuditorFirmId contextRef="cref_1268430831" id="ixv-11950">1171</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="cref_1268430831" id="ixv-11951">San Mateo, California</dei:AuditorLocation>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-11952"
      unitRef="uref_518000893">385535</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11953"
      unitRef="uref_518000893">31139</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-11954"
      unitRef="uref_518000893">13363977</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11955"
      unitRef="uref_518000893">1837705</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <advb:DueFromDiscontinuedOperations
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11956"
      unitRef="uref_518000893">16349752</advb:DueFromDiscontinuedOperations>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11957"
      unitRef="uref_518000893">4163727</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-11958"
      unitRef="uref_518000893">13749512</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11959"
      unitRef="uref_518000893">22382323</us-gaap:AssetsCurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-11960"
      unitRef="uref_518000893">1204</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11961"
      unitRef="uref_518000893">479772</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-11962"
      unitRef="uref_518000893">1204</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11963"
      unitRef="uref_518000893">479772</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-11964"
      unitRef="uref_518000893">13750716</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11965"
      unitRef="uref_518000893">22862095</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_1380723918"
      decimals="0"
      id="fc_191820595"
      unitRef="uref_518000893">1473989</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="fc_1884851114"
      unitRef="uref_518000893">780831</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11968"
      unitRef="uref_518000893">18458049</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-11969"
      unitRef="uref_518000893">1473989</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11970"
      unitRef="uref_518000893">19238880</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="cref_958460008"
      decimals="0"
      id="ixv-11971"
      unitRef="uref_518000893">69975</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11972"
      unitRef="uref_518000893">75676</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11973"
      unitRef="uref_518000893">145651</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-11974"
      unitRef="uref_518000893">1473989</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11975"
      unitRef="uref_518000893">19384531</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1380723918"
      decimals="3"
      id="fc_1857452080"
      unitRef="uref_1427765276">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1096537008"
      decimals="3"
      id="fc_1808618487"
      unitRef="uref_1427765276">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1380723918"
      decimals="INF"
      id="fc_1427537372"
      unitRef="uref_1493501123">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1096537008"
      decimals="INF"
      id="fc_1344104536"
      unitRef="uref_1493501123">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1380723918"
      decimals="INF"
      id="fc_79949418"
      unitRef="uref_1493501123">1652133</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_1380723918"
      decimals="INF"
      id="fc_1985688321"
      unitRef="uref_1493501123">1652133</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1096537008"
      decimals="INF"
      id="fc_118352444"
      unitRef="uref_1493501123">1082000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_1096537008"
      decimals="INF"
      id="fc_554093189"
      unitRef="uref_1493501123">1082000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="cref_1380723918"
      decimals="0"
      id="fc_639943382"
      unitRef="uref_518000893">1652</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="cref_1096537008"
      decimals="0"
      id="fc_1013319968"
      unitRef="uref_518000893">1082</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-11986"
      unitRef="uref_518000893">23862166</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11987"
      unitRef="uref_518000893">21367836</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-11988"
      unitRef="uref_518000893">-12555967</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11989"
      unitRef="uref_518000893">-19233044</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-11990"
      unitRef="uref_518000893">968876</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11991"
      unitRef="uref_518000893">1341690</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-11992"
      unitRef="uref_518000893">12276727</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11993"
      unitRef="uref_518000893">3477564</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-11994"
      unitRef="uref_518000893">13750716</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-11995"
      unitRef="uref_518000893">22862095</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-11997"
      unitRef="uref_518000893">127637</us-gaap:Revenues>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-11998"
      unitRef="uref_518000893">1734009</us-gaap:ShareBasedCompensation>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-11999"
      unitRef="uref_518000893">4627170</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12000"
      unitRef="uref_518000893">1086470</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12001"
      unitRef="uref_518000893">6361179</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12002"
      unitRef="uref_518000893">1086470</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12003"
      unitRef="uref_518000893">-6233542</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12004"
      unitRef="uref_518000893">-1086470</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12005"
      unitRef="uref_518000893">-7014</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12006"
      unitRef="uref_518000893">-21925</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12007"
      unitRef="uref_518000893">-28939</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12008"
      unitRef="uref_518000893">-6262481</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12009"
      unitRef="uref_518000893">-1086470</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12010"
      unitRef="uref_518000893">-1205</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12011"
      unitRef="uref_518000893">-6261276</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12012"
      unitRef="uref_518000893">-1086470</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12013"
      unitRef="uref_518000893">-1077064</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12014"
      unitRef="uref_518000893">-2172499</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12015"
      unitRef="uref_518000893">14015417</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12016"
      unitRef="uref_518000893">12938353</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12017"
      unitRef="uref_518000893">-2172499</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1268430831"
      decimals="0"
      id="fc_1281183005"
      unitRef="uref_518000893">6677077</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1127853967"
      decimals="0"
      id="fc_69219705"
      unitRef="uref_518000893">-3258969</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12020"
      unitRef="uref_518000893">-372814</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12021"
      unitRef="uref_518000893">218346</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12022"
      unitRef="uref_518000893">6304263</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12023"
      unitRef="uref_518000893">-3040623</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="cref_1268430831"
      decimals="2"
      id="fc_1630484428"
      unitRef="uref_1427765276">-5</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="cref_1268430831"
      decimals="2"
      id="fc_1295661221"
      unitRef="uref_1427765276">-5</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="cref_1127853967"
      decimals="2"
      id="fc_23137350"
      unitRef="uref_1427765276">-1.06</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="cref_1127853967"
      decimals="2"
      id="fc_2080613918"
      unitRef="uref_1427765276">-1.06</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="cref_1268430831"
      decimals="2"
      id="fc_776335972"
      unitRef="uref_1427765276">10.33</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="cref_1268430831"
      decimals="2"
      id="fc_726916121"
      unitRef="uref_1427765276">10.33</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="cref_1127853967"
      decimals="2"
      id="fc_250126196"
      unitRef="uref_1427765276">-2.12</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="cref_1127853967"
      decimals="2"
      id="fc_1921281851"
      unitRef="uref_1427765276">-2.12</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1268430831"
      decimals="2"
      id="fc_1324410395"
      unitRef="uref_1427765276">5.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1268430831"
      decimals="2"
      id="fc_370814422"
      unitRef="uref_1427765276">5.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1127853967"
      decimals="2"
      id="fc_307002805"
      unitRef="uref_1427765276">-3.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1127853967"
      decimals="2"
      id="fc_900194652"
      unitRef="uref_1427765276">-3.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1268430831"
      decimals="0"
      id="fc_24468988"
      unitRef="uref_1493501123">1252727</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1268430831"
      decimals="0"
      id="fc_2117807913"
      unitRef="uref_1493501123">1252727</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1127853967"
      decimals="0"
      id="fc_1893897237"
      unitRef="uref_1493501123">1026285</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1127853967"
      decimals="0"
      id="fc_1167701535"
      unitRef="uref_1493501123">1026285</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="cref_1559650067"
      decimals="0"
      id="fc_1377638562"
      unitRef="uref_1493501123">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1559650067"
      decimals="0"
      id="fc_1559650067"
      unitRef="uref_518000893">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_2016794188"
      decimals="0"
      id="fc_2016794188"
      unitRef="uref_518000893">16512989</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_871642115"
      decimals="0"
      id="ixv-12044"
      unitRef="uref_518000893">1123344</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1184248197"
      decimals="0"
      id="ixv-12045"
      unitRef="uref_518000893">-15974075</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1440922954"
      decimals="0"
      id="ixv-12046"
      unitRef="uref_518000893">1663258</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="cref_488074029"
      decimals="0"
      id="ixv-12047"
      unitRef="uref_518000893">-3258969</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12048"
      unitRef="uref_518000893">-3258969</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_770078133"
      decimals="0"
      id="fc_1612819270"
      unitRef="uref_1493501123">82000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_770078133"
      decimals="0"
      id="fc_770078133"
      unitRef="uref_518000893">82</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_71328825"
      decimals="0"
      id="fc_71328825"
      unitRef="uref_518000893">4854847</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12052"
      unitRef="uref_518000893">4854929</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="cref_1755322658"
      decimals="0"
      id="ixv-12053"
      unitRef="uref_518000893">218346</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12054"
      unitRef="uref_518000893">218346</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="cref_207845589"
      decimals="0"
      id="fc_2024752313"
      unitRef="uref_1493501123">1082000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_207845589"
      decimals="0"
      id="fc_362126174"
      unitRef="uref_518000893">1082</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_969532781"
      decimals="0"
      id="fc_1697903215"
      unitRef="uref_518000893">21367836</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_327918837"
      decimals="0"
      id="ixv-12058"
      unitRef="uref_518000893">1341690</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_940316359"
      decimals="0"
      id="ixv-12059"
      unitRef="uref_518000893">-19233044</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12060"
      unitRef="uref_518000893">3477564</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_207845589"
      decimals="0"
      id="fc_1743990980"
      unitRef="uref_1493501123">1082000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_207845589"
      decimals="0"
      id="fc_207845589"
      unitRef="uref_518000893">1082</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_969532781"
      decimals="0"
      id="fc_969532781"
      unitRef="uref_518000893">21367836</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_327918837"
      decimals="0"
      id="ixv-12064"
      unitRef="uref_518000893">1341690</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_940316359"
      decimals="0"
      id="ixv-12065"
      unitRef="uref_518000893">-19233044</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12066"
      unitRef="uref_518000893">3477564</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1756868353"
      decimals="0"
      id="ixv-12067"
      unitRef="uref_518000893">6677077</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12068"
      unitRef="uref_518000893">6677077</us-gaap:NetIncomeLoss>
    <advb:StockIssuedDuringPeriodSharesPrivatePlacement
      contextRef="cref_805845135"
      decimals="0"
      id="fc_785858763"
      unitRef="uref_1493501123">200000</advb:StockIssuedDuringPeriodSharesPrivatePlacement>
    <advb:StockIssuedDuringPeriodValuePrivatePlacement
      contextRef="cref_805845135"
      decimals="0"
      id="fc_9630985"
      unitRef="uref_518000893">200</advb:StockIssuedDuringPeriodValuePrivatePlacement>
    <advb:StockIssuedDuringPeriodValuePrivatePlacement
      contextRef="cref_1796841557"
      decimals="0"
      id="fc_876291995"
      unitRef="uref_518000893">247800</advb:StockIssuedDuringPeriodValuePrivatePlacement>
    <advb:StockIssuedDuringPeriodValuePrivatePlacement
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12072"
      unitRef="uref_518000893">248000</advb:StockIssuedDuringPeriodValuePrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="cref_805845135"
      decimals="0"
      id="fc_1013726955"
      unitRef="uref_1493501123">82536</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_805845135"
      decimals="0"
      id="fc_370992816"
      unitRef="uref_518000893">83</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_1796841557"
      decimals="0"
      id="fc_1884897091"
      unitRef="uref_518000893">499917</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12076"
      unitRef="uref_518000893">500000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="cref_805845135"
      decimals="0"
      id="fc_1923676656"
      unitRef="uref_1493501123">17597</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_805845135"
      decimals="0"
      id="fc_1311257128"
      unitRef="uref_518000893">17</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_1796841557"
      decimals="0"
      id="fc_266513493"
      unitRef="uref_518000893">-17</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="cref_805845135"
      decimals="0"
      id="fc_103096211"
      unitRef="uref_1493501123">270000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_805845135"
      decimals="0"
      id="fc_1609136595"
      unitRef="uref_518000893">270</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_1796841557"
      decimals="0"
      id="fc_1526602125"
      unitRef="uref_518000893">12621</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12083"
      unitRef="uref_518000893">12891</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1796841557"
      decimals="0"
      id="fc_1430973038"
      unitRef="uref_518000893">1734009</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12085"
      unitRef="uref_518000893">1734009</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="cref_471026296"
      decimals="0"
      id="ixv-12086"
      unitRef="uref_518000893">-372814</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12087"
      unitRef="uref_518000893">-372814</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="cref_1515466520"
      decimals="0"
      id="fc_1849258122"
      unitRef="uref_1493501123">1652133</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1515466520"
      decimals="0"
      id="fc_1515466520"
      unitRef="uref_518000893">1652</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1527988905"
      decimals="0"
      id="fc_1527988905"
      unitRef="uref_518000893">23862166</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1622799614"
      decimals="0"
      id="ixv-12091"
      unitRef="uref_518000893">968876</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1044073967"
      decimals="0"
      id="ixv-12092"
      unitRef="uref_518000893">-12555967</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12093"
      unitRef="uref_518000893">12276727</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12095"
      unitRef="uref_518000893">6677077</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12096"
      unitRef="uref_518000893">-3258969</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12097"
      unitRef="uref_518000893">12938353</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12098"
      unitRef="uref_518000893">-2172499</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12099"
      unitRef="uref_518000893">-6261276</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12100"
      unitRef="uref_518000893">-1086470</us-gaap:IncomeLossFromContinuingOperations>
    <advb:CommonStockIssuedForCommitmentFee
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12101"
      unitRef="uref_518000893">500000</advb:CommonStockIssuedForCommitmentFee>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12102"
      unitRef="uref_518000893">1734009</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12103"
      unitRef="uref_518000893">-1205</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12104"
      unitRef="uref_518000893">2918909</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12105"
      unitRef="uref_518000893">-579866</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12106"
      unitRef="uref_518000893">1837705</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12107"
      unitRef="uref_518000893">-431644</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12108"
      unitRef="uref_518000893">615806</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12109"
      unitRef="uref_518000893">-961341</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12110"
      unitRef="uref_518000893">-2308369</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12111"
      unitRef="uref_518000893">-985602</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12112"
      unitRef="uref_518000893">-3516686</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12113"
      unitRef="uref_518000893">-1946943</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12114"
      unitRef="uref_518000893">-5825055</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="cref_1268430831"
      decimals="0"
      id="fc_1604790368"
      unitRef="uref_518000893">2581850</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12116"
      unitRef="uref_518000893">-2581850</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="cref_1268430831"
      decimals="0"
      id="fc_1047406491"
      unitRef="uref_518000893">75763</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12118"
      unitRef="uref_518000893">-31650</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12119"
      unitRef="uref_518000893">-2506087</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12120"
      unitRef="uref_518000893">-31650</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12121"
      unitRef="uref_518000893">248000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12122"
      unitRef="uref_518000893">5493800</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12123"
      unitRef="uref_518000893">1078215</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12124"
      unitRef="uref_518000893">274975</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12125"
      unitRef="uref_518000893">1326215</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12126"
      unitRef="uref_518000893">5768775</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12127"
      unitRef="uref_518000893">641757</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12128"
      unitRef="uref_518000893">165526</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12129"
      unitRef="uref_518000893">1967972</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12130"
      unitRef="uref_518000893">5934301</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12131"
      unitRef="uref_518000893">-10479</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12132"
      unitRef="uref_518000893">-22843</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12133"
      unitRef="uref_518000893">218346</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12134"
      unitRef="uref_518000893">-2518380</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12135"
      unitRef="uref_518000893">295942</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12136"
      unitRef="uref_518000893">2903915</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="cref_1440922954"
      decimals="0"
      id="ixv-12137"
      unitRef="uref_518000893">2607973</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12138"
      unitRef="uref_518000893">385535</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12139"
      unitRef="uref_518000893">2903915</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12140"
      unitRef="uref_518000893">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12141"
      unitRef="uref_518000893">2872776</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12142"
      unitRef="uref_518000893">385535</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12143"
      unitRef="uref_518000893">31139</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <advb:CommonStockIssuedInSettlementOfCommitmentFees
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12144"
      unitRef="uref_518000893">500000</advb:CommonStockIssuedInSettlementOfCommitmentFees>
    <advb:CommonStockIssuedForAcquisitionOfAcellent
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12145"
      unitRef="uref_518000893">12891</advb:CommonStockIssuedForAcquisitionOfAcellent>
    <advb:StockBasedCompensation
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12146"
      unitRef="uref_518000893">1734009</advb:StockBasedCompensation>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="cref_1268430831" id="ixv-6908">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;1.&lt;/td&gt; &lt;td&gt;ORGANIZATION AND PRINCIPAL ACTIVITIES&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;Organization&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Advanced Biomed Inc. (the &#x201c;Company&#x201d;) was incorporated in the State of Nevada on July 16, 2021. The Company is a holding company and conducts its operations through its subsidiaries. The Company&#x2019;s common stock is listed on the Nasdaq Capital Market under the symbol &#x201c;ADVB.&#x201d; &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Historically, the Company conducted biotechnology operations primarily through Advanced Biomed Inc. (Taiwan) and Advanced Biomed HK Limited and its subsidiary, Shanghai Sglcell Biotech Co., Ltd. These operations were principally engaged in the research and development of microfluidic technologies and cancer screening and related medical device applications.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;Strategic Restructuring and Discontinued Operations&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;During the fiscal year ended June 30, 2026, the Company undertook a strategic restructuring to transition its business focus from its historical biotechnology operations to artificial intelligence and financial algorithmic software-related activities.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; On December 23, 2025, the Company entered into a sale and purchase agreement to dispose of its 100% equity interest in Advanced Biomed HK Limited, including its subsidiary, Shanghai Sglcell Biotech Co., Ltd, to an independent third party for total cash consideration of $23,000. The transaction was completed on December 31, 2025. On June 30, 2026, the Company completed the disposition of its 100% of equity interest in Advanced Biomed Inc. (Taiwan) to an independent third party for aggregate cash consideration of $490,000. Following these dispositions, the Company ceased its historical biotechnology operations. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company determined that the dispositions represented a strategic shift that had a major effect on its operations and financial results. Accordingly, the historical results of operations and cash flows attributable to these operations have been presented as discontinued operations for all periods presented in the accompanying consolidated financial statements in accordance with ASC 205-20, &lt;i&gt;Presentation of Financial Statements &#x2014; Discontinued Operations.&lt;/i&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;See Note 5 &#x2014; Discontinued Operations for additional information.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;Acquisition of Acellent &lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; In April 2026, the Company acquired 100% of the equity interest in Acellent Technologies (Hong Kong) Co. Limited (&#x201c;Acellent&#x201d;), a Hong Kong technology company focused on artificial intelligence and financial algorithmic software-related applications, from an independent individual. Following the acquisition, Acellent became a wholly owned subsidiary of the Company. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; In connection with the transaction, the Company issued 270,000 shares of common stock of the Company as the consideration. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Following the acquisition, the Company&#x2019;s continuing operations are primarily focused on technology-related activities utilizing the developing software platform. During the year ended June 30, 2026, the Company commenced generating revenue from these continuing operations.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;See Note 4 &#x2014; Acquisition of Acellent for additional information.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;       &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;January 2026 Private Placement&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; In January 2026, the Company entered into a Securities Purchase Agreement with certain accredited investors. Pursuant to the agreement, the Company issued 200,000 shares of common stock (representing 4,000,000 shares on a pre-split basis) for gross proceeds of $248,000. The proceeds from this private placement are intended to be used for general corporate purposes and working capital. All share counts related to this offering have been retroactively adjusted to reflect the 1-for-20 Reverse Split that occurred on February 20, 2026. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;Issuance of Common Stock for Commitment Fee&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; In January 2026, prior to the Reverse Split, the Company issued shares of common stock with an aggregate fair value of $500,000 to an institutional investor as a commitment fee in connection with a securities purchase agreement. The issuance was recognized as a non-cash financing expense. The underlying share count has been retroactively restated to reflect the Reverse Split. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; On February 3, 2026, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of Nevada to effect a 1-for-20 reverse stock split of its common stock. The Reverse Split became effective at the open of trading on The Nasdaq Capital Market on February 20, 2026. All share and per-share amounts in the consolidated financial statements and accompanying notes have been retroactively adjusted to reflect the Reverse Split for all periods presented. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company and list of its subsidiaries consolidated in current year and as of the report date were shown below:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 16%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Name of entity&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 16%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Place of &lt;br/&gt; incorporation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 16%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Ownership &lt;br/&gt; interest as of &lt;br/&gt; June 30, &lt;br/&gt; 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 15%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Ownership &lt;br/&gt; interest as of &lt;br/&gt; June 30, &lt;br/&gt; 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 33%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Principal activities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&lt;span style="font-size: 10pt;"&gt;Advanced Biomed Inc.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Nevada, United States&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:fc_2069444419;"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:fc_2017348691;"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Investment holding&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&lt;span style="font-size: 10pt;"&gt;Acellent Technologies (Hong Kong) Co. Limited (1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Hong Kong&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:fc_1263417979;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Artificial intelligence and financial algorithmic software-related activities and agency services&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Advanced Biomed Inc. (Taiwan) (2)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Taiwan&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:fc_1497991597;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Research and development of microfluidic technologies and cancer screening-related medical device applications&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: White;"&gt; &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Advanced Biomed HK Limited (3)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Hong Kong&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:fc_1454131596;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Investment holding in the biotechnology sector&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&lt;span style="font-size: 10pt;"&gt;Shanghai Sglcell Biotech Co., Ltd. (3)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Mainland China&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:fc_936064758;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;100% (indirect)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Biotechnology-related market development and clinical activities&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;(1)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;The Company acquired 100% of the equity interests in Acellent Technologies (Hong Kong) Co. Limited in April 2026.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;(2)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;The Company disposed of its entire equity interest in Advanced Biomed Inc. (Taiwan) on June 30, 2026.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;(3)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;The Company disposed of its entire equity interest in Advanced Biomed HK Limited, including its wholly owned subsidiary, Shanghai Sglcell Biotech Co., Ltd., in December 2025.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The results of operations of the former biotechnology subsidiaries identified in (2) and (3) above have been presented as discontinued operations for all periods presented. See Note 5 &#x2014; Discontinued Operations.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="cref_1268430831" id="ixv-12147">2021-07-16</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="cref_554751373"
      decimals="2"
      id="ixv-12148"
      unitRef="uref_1766841203">1</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="cref_906810478"
      decimals="0"
      id="ixv-12149"
      unitRef="uref_518000893">23000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="cref_554751373"
      decimals="2"
      id="ixv-12150"
      unitRef="uref_1766841203">1</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="cref_1904813312"
      decimals="0"
      id="ixv-12151"
      unitRef="uref_518000893">490000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="cref_185613871"
      decimals="2"
      id="ixv-12152"
      unitRef="uref_1766841203">1</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="cref_1907271931"
      decimals="0"
      id="ixv-12153"
      unitRef="uref_1493501123">270000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_387884904"
      decimals="0"
      id="ixv-12154"
      unitRef="uref_1493501123">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_1880182860"
      decimals="0"
      id="ixv-12155"
      unitRef="uref_1493501123">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_1880182860"
      decimals="0"
      id="ixv-12156"
      unitRef="uref_518000893">248000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="cref_2137289145" id="ixv-12157">1-for-20</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1379153066"
      decimals="0"
      id="ixv-12158"
      unitRef="uref_518000893">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="cref_91010303" id="ixv-12159">1-for-20</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock contextRef="cref_1268430831" id="ixv-6972">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company and list of its subsidiaries consolidated in current year and as of the report date were shown below:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 16%; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Name of entity&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 16%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Place of &lt;br/&gt; incorporation&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 16%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Ownership &lt;br/&gt; interest as of &lt;br/&gt; June 30, &lt;br/&gt; 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 15%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Ownership &lt;br/&gt; interest as of &lt;br/&gt; June 30, &lt;br/&gt; 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 33%; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Principal activities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&lt;span style="font-size: 10pt;"&gt;Advanced Biomed Inc.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Nevada, United States&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:fc_2069444419;"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:fc_2017348691;"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Investment holding&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&lt;span style="font-size: 10pt;"&gt;Acellent Technologies (Hong Kong) Co. Limited (1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Hong Kong&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:fc_1263417979;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Artificial intelligence and financial algorithmic software-related activities and agency services&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Advanced Biomed Inc. (Taiwan) (2)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Taiwan&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:fc_1497991597;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Research and development of microfluidic technologies and cancer screening-related medical device applications&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: White;"&gt; &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Advanced Biomed HK Limited (3)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Hong Kong&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:fc_1454131596;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Investment holding in the biotechnology sector&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&lt;span style="font-size: 10pt;"&gt;Shanghai Sglcell Biotech Co., Ltd. (3)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Mainland China&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:fc_936064758;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;100% (indirect)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; vertical-align: top;"&gt;&lt;span style="font-size: 10pt;"&gt;Biotechnology-related market development and clinical activities&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;(1)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;The Company acquired 100% of the equity interests in Acellent Technologies (Hong Kong) Co. Limited in April 2026.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;(2)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;The Company disposed of its entire equity interest in Advanced Biomed Inc. (Taiwan) on June 30, 2026.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;(3)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;The Company disposed of its entire equity interest in Advanced Biomed HK Limited, including its wholly owned subsidiary, Shanghai Sglcell Biotech Co., Ltd., in December 2025.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="cref_892504388" id="fc_2068580999">Nevada, United States</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="cref_892504388" id="ixv-7021">Investment holding</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="cref_378644450" id="fc_197249230">Hong Kong</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="cref_378644450"
      decimals="2"
      id="fc_1149370131"
      unitRef="uref_1766841203">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="cref_378644450" id="fc_378644450">Artificial intelligence and financial algorithmic software-related activities and agency services</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="cref_1189438897" id="fc_1488513075">Taiwan</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="cref_492101464"
      decimals="2"
      id="fc_492101464"
      unitRef="uref_1766841203">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="cref_1189438897" id="fc_1189438897">Research and development of microfluidic technologies and cancer screening-related medical device applications</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="cref_951683079" id="fc_860594818">Hong Kong</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="cref_23459831"
      decimals="2"
      id="fc_23459831"
      unitRef="uref_1766841203">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="cref_951683079" id="fc_951683079">Investment holding in the biotechnology sector</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="cref_1877900993" id="fc_1399799817">Mainland China</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="cref_372193311"
      decimals="2"
      id="fc_372193311"
      unitRef="uref_1766841203">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="cref_1877900993" id="fc_1877900993">Biotechnology-related market development and clinical activities</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="cref_1268430831" id="ixv-7122">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;2.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;LIQUIDITY AND GOING CONCERN&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates the continuation of the Company as a going concern and the realization of assets and settlement of liabilities in the ordinary course of business.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;During the fiscal year ended June 30, 2026, the Company completed the disposition of its historical biotechnology operations and transitioned its operations toward artificial intelligence and financial algorithmic software-related activities. In April 2026, the Company acquired Acellent and commenced generating revenue from technology-related activities utilizing the software platform.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; For the year ended June 30, 2026, although the Company reported net income of $6,677,077, this was primarily attributable to a gain of $14,015,417 generated from the disposal of Advanced Biomed HK Limited and its subsidiary and Advanced Biomed Inc. (Taiwan) during the year. In addition, the Company had net cash outflows of $1,946,943 from operating activities for the year ended June 30, 2026. To improve its liquidity, the Company completed a private placement in January 2026, raising gross proceeds of $248,000. Additionally, the Company implemented a 1-for-20 reverse stock split in February 2026 to maintain its listing status and improve its capital structure. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company&#x2019;s ability to meet its future liquidity requirements will depend on, among other factors, its ability to generate cash flows from its continuing operations and, if necessary, obtain additional financing. Management intends to fund the Company&#x2019;s operations through available cash resources, cash flows generated from operations and, if necessary, additional equity or other financing arrangements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Based on its current operating plans, available financial resources and expected cash requirements, management believes that the Company has sufficient liquidity to meet its obligations for at least twelve months from the date the consolidated financial statements are issued.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12167"
      unitRef="uref_518000893">6677077</us-gaap:NetIncomeLoss>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12168"
      unitRef="uref_518000893">14015417</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12169"
      unitRef="uref_518000893">-1946943</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="cref_522535513"
      decimals="0"
      id="ixv-12170"
      unitRef="uref_518000893">248000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="cref_1619078810" id="ixv-12171">1-for-20</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="cref_1268430831" id="ixv-7140">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;3.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(a)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Basis of Presentation&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(b)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Principles of Consolidation&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The consolidated financial statements include the financial statements of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Subsidiaries are consolidated from the date the Company obtains control and cease to be consolidated from the date the Company loses control. The results of operations of subsidiaries disposed of during the year presented are included in the consolidated financial statements through the respective dates on which control ceased, as applicable.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(c)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Discontinued Operations&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company reports a disposal of a component or group of components as discontinued operations when the disposal represents a strategic shift that has, or will have, a major effect on the Company&#x2019;s operations and financial results. The results of operations of a component classified as discontinued operations are presented separately from continuing operations in the consolidated statements of operations and comprehensive income (loss) for all periods presented. Cash flows attributable to discontinued operations are separately presented in the consolidated statements of cash flows.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;/p&gt;      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;During the year ended June 30, 2026, the Company completed the dispositions of Advanced Biomed HK Limited and its subsidiary, Shanghai Sglcell Biotech Co., Ltd., and Advanced Biomed Inc. (Taiwan), which comprised the Company&#x2019;s historical biotechnology operations. The Company determined that these dispositions represented a strategic shift that had a major effect on the Company&#x2019;s operations and financial results. Accordingly, the results of these historical biotechnology operations have been presented as discontinued operations for all periods presented in accordance with ASC 205-20, &lt;i&gt;Presentation of Financial Statements &#x2014; Discontinued Operations.&lt;/i&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;See Note 5 &#x2014; Discontinued Operations for additional information.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(d)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Use of Estimates&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of income and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Significant estimates and assumptions reflected in the Company&#x2019;s consolidated financial statements include, but are not limited to, allowance for expected credit losses, stock-based compensation, interest rate of lease and gain on disposal of subsidiaries.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(e)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Cash&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Cash consists of cash on hand and demand deposits with financial institutions that are unrestricted as to withdrawal and use.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company maintains its cash with financial institutions that management believes to be of high credit quality. The Company monitors the financial condition of these institutions and has not experienced any losses on such accounts.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(f)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Foreign Currency Translation and Transactions&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The accompanying consolidated financial statements are presented in U.S. dollars (&#x201c;US$&#x201d;), which is the reporting currency of the Company. The functional currency of the Company is the U.S. dollar. The functional currency of Acellent, the Company&#x2019;s Hong Kong subsidiary acquired in April 2026, is the Hong Kong dollar (&#x201c;HKD&#x201d;). Certain subsidiaries included in the consolidated financial statements prior to their dispositions during the year ended June 30, 2026 also used currencies other than the U.S. dollar as their functional currencies.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Assets and liabilities of subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars at the exchange rates in effect at the balance sheet date. Revenues and expenses are translated at the exchange rates in effect on the dates of the transactions or, when appropriate, at average exchange rates for the applicable reporting period. Translation adjustments resulting from the translation of the financial statements of foreign subsidiaries are recorded in other comprehensive income (loss) and accumulated in accumulated other comprehensive income, a component of stockholders&#x2019; equity.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Transactions denominated in currencies other than an entity&#x2019;s functional currency are initially recorded at the exchange rate in effect on the transaction date. Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured at the exchange rate in effect at the balance sheet date, and resulting foreign currency transaction gains or losses are recognized in the consolidated statements of operations and comprehensive income (loss).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;       &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The following table sets forth the exchange rates used in preparing the accompanying consolidated financial statements:&lt;/p&gt;  &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;June 30, &lt;br/&gt;     2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;June 30, &lt;br/&gt;     2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: justify;"&gt;US$ to NT$ fiscal year-end rate&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;31.8500&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;29.1800&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;US$ to NT$ average rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;31.0413&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;32.0919&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify;"&gt;US$ to HKD fiscal year-end rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.8420&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.8500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;US$ to HKD average rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.8347&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.7900&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(g)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Fair Value Measurements&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company follows ASC 820, Fair Value Measurement, which defines fair value, establishes a framework for measuring fair value and establishes a fair value hierarchy that prioritizes the inputs used in valuation techniques. The three levels of the fair value hierarchy are as follows:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Level 1 &#x2014; Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Level 2 &#x2014; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Level 3 &#x2014; Unobservable inputs for the asset or liability that are significant to the fair value measurement.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The classification of a fair value measurement within the hierarchy is based on the lowest level input that is significant to the measurement.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The carrying amounts of the Company&#x2019;s short-term financial assets and liabilities approximate their fair values because of the short-term nature of these instruments.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(h)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Related Parties&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company identifies related parties and accounts for and discloses related-party transactions in accordance with ASC 850, Related Party Disclosures. Related parties generally include the Company&#x2019;s directors and executive officers, principal stockholders, their immediate family members, and entities that are controlled by or under common control with such parties.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Transactions with related parties are recorded based on the terms of the underlying arrangements. Material related-party transactions and balances are disclosed in the accompanying consolidated financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(i)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Credit Losses&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company accounts for credit losses on financial assets measured at amortized cost in accordance with ASC 326, &lt;i&gt;Financial Instruments &#x2014; Credit Losses&lt;/i&gt;. The Company estimates expected credit losses based on relevant information available about past events, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amounts.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company evaluates amount due from related parties and other applicable financial assets for expected credit losses on an individual or collective basis, as appropriate, considering factors such as historical payment experience, the financial condition and creditworthiness of the counterparties, the aging and nature of the outstanding balances, current economic conditions, and reasonable and supportable forecasts of future economic conditions.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;An allowance for credit losses is recorded as a reduction of the carrying amount of the related financial asset, with the corresponding credit loss expense recognized in the consolidated statements of operations and comprehensive income (loss). Financial assets are written off against the allowance when they are deemed uncollectible. Recoveries of amounts previously written off are recognized when received.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt;       &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(j)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Revenue Recognition&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company recognizes revenue in accordance with ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;. Revenue is recognized when control of the promised services is transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those services.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company recognizes revenue in accordance with ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;. The five-step model defined by ASC 606 requires the Company to (1) identify its contracts with customers, (2) identify its performance obligations under those contracts, (3) determine the transaction prices of those contracts, (4) allocate the transaction prices to its performance obligations in those contracts, and (5) recognize revenue when each performance obligation under those contracts is satisfied.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;A contract contains a promise (or promises) to transfer goods or services to a customer. A performance obligation is a promise (or a group of promises) that is distinct. The transaction price is the amount of consideration a company expects to be entitled from a customer in exchange for providing the goods or services.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company enters into a distinct contract with its customers for the provision of agency service.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Transaction price is the amount of consideration in the contract to which the Company expects to be entitled in exchange for transferring the promised goods or services. The transaction price is fixed. The agency fee was one-off, non-refundable right for the agent sourcing customers for the Company.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Revenue is recognized when the Company satisfies a performance obligation by transferring the promised service to a customer, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for that service.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company&#x2019;s revenue from continuing operations is primarily derived from agency services provided through its subsidiary, Acellent. The Company identifies the services promised under each customer arrangement and recognizes the related agency fee when the applicable performance obligation has been satisfied in accordance with the terms of that arrangement (point in time).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Revenue from contracts with customers consisted of the following:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-weight: bold;"&gt;Revenue by major source&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;Year ended &lt;br/&gt; June 30, &lt;br/&gt; 2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;Year ended &lt;br/&gt; June 30, &lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt;"&gt;Agency fee revenue &#x2013; point in time&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;127,637&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_289217852;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;Total revenue&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;127,637&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_64957701;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(k)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Stock-Based Compensation&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company measures stock-based compensation at the fair value of the equity instruments issued and recognizes the resulting expense over the period in which the related services are received under ASC 718. Stock-based compensation expense is included in operating expenses in the consolidated statements of operations and comprehensive income (loss).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt;       &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(l)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Impairment of Long-Lived Assets&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company reviews its long-lived assets, including finite-lived intangible assets and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;When indicators of impairment exist, recoverability is assessed by comparing the carrying amount of the asset or asset group to the estimated undiscounted future cash flows expected to result from its use and eventual disposition. If the carrying amount is not recoverable, an impairment loss is recognized for the amount by which the carrying amount exceeds its fair value. Fair value is determined using appropriate valuation techniques based on the facts and circumstances.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(m)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Commitments and Contingencies&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company is subject to commitments and contingencies arising in the ordinary course of business, including legal proceedings, claims, contractual commitments and other matters. The Company records an accrual for a loss contingency when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. If a loss is reasonably possible but not probable, or if a loss is probable but the amount cannot be reasonably estimated, the nature of the contingency and an estimate of the possible loss or range of loss, if estimable, are disclosed in the notes to the consolidated financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company evaluates its commitments and contingencies based on the facts and circumstances available at each reporting date and revises its estimates as additional information becomes available.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(n)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Income Taxes&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company accounts for income taxes in accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards, if any. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;A valuation allowance is established against deferred tax assets when, based on the weight of available positive and negative evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluates the realizability of its deferred tax assets at each reporting date and adjusts the valuation allowance, as necessary, based on changes in facts and circumstances.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The Company recognizes the effect of uncertain tax positions when it is more likely than not, based on the technical merits, that the tax position will be sustained upon examination by the relevant taxing authority. A tax position that meets the recognition threshold is measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(o)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Earnings (Loss) Per Share&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Basic earnings (loss) per share is computed by dividing income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Diluted earnings (loss) per share is computed by dividing income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for the effect of potentially dilutive securities, if any. Potential common shares are excluded from the computation of diluted earnings (loss) per share when their effect would be anti-dilutive.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Basic and diluted earnings (loss) per share from continuing operations and discontinued operations are presented separately in accordance with U.S. GAAP.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;All share and per-share amounts presented in the accompanying consolidated financial statements have been retrospectively adjusted, as applicable, to reflect the reverse stock split described below.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt;       &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(p)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Comprehensive Income (Loss)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) includes foreign currency translation adjustments arising from the translation of the financial statements of foreign subsidiaries whose functional currencies are other than the U.S. dollar.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Foreign currency translation adjustments are reported as a component of other comprehensive income (loss), and the cumulative amount is reported in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(q)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Segment Reporting&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company determines its operating segments in accordance with ASC 280, Segment Reporting, based on the manner in which the chief operating decision maker (&#x201c;CODM&#x201d;) manages the Company and evaluates operating performance. Operating segments are components of an enterprise for which separate financial information is available and is regularly evaluated by the CODM in deciding how to allocate resources and assess performance.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The Company has one reportable segment for its continuing operations, consisting primarily of its technology and software-related operations. The Company&#x2019;s historical biotechnology operations, which were disposed of during the year ended June 30, 2026, are presented as discontinued operations and are not included in the Company&#x2019;s continuing reportable segment. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(r)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Reverse Stock Split&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; On February 20, 2026, the Company effected a 1-for-20 reverse stock split of its common stock. The reverse stock split reduced the number of issued and outstanding shares of common stock on a proportionate basis and did not change the par value per share of the Company&#x2019;s common stock. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;All share and per-share amounts presented in the accompanying consolidated financial statements and related notes have been retrospectively adjusted, as applicable, to reflect the reverse stock split for all periods presented.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(s)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Recent Accounting Pronouncements&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In October 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-06, Disclosure Improvements &#x2014; Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative. The amendments incorporate certain disclosure and presentation requirements previously contained in SEC regulations into the FASB Accounting Standards Codification. For entities subject to the SEC&#x2019;s existing disclosure requirements, the effective date for each amendment will be the date on which the SEC removes the related disclosure requirement from its rules. The Company does not expect the adoption of ASU 2023-06 to have a material impact on its consolidated financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) &#x2014; Improvements to Income Tax Disclosures, which enhances income tax disclosures, primarily related to the rate reconciliation and income taxes paid. The amendments are effective for public business entities for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09 during the year ended June 30, 2026. The adoption did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In March 2024, the FASB issued ASU 2024-01, Compensation &#x2014; Stock Compensation (Topic 718) &#x2014; Scope Application of Profits Interest and Similar Awards. The amendments provide illustrative guidance to assist entities in determining whether profits interest and similar awards should be accounted for as share-based payment arrangements under ASC Topic 718. The amendments are effective for public business entities for annual periods beginning after December 15, 2024, including interim periods within those annual periods. The Company adopted ASU 2024-01 during the year ended June 30, 2026. The adoption did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;       &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In March 2024, the FASB issued ASU 2024-02, Codification Improvements &#x2014; Amendments to Remove References to the Concepts Statements. The amendments remove references to various FASB Concepts Statements from the Codification and make other conforming amendments. The amendments are effective for public business entities for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. The Company adopted ASU 2024-02 during the year ended June 30, 2026. The adoption did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. In January 2025, the FASB issued ASU 2025-01, Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarifies the effective date of ASU 2024-03 for entities with non-calendar year ends. The amendments require public business entities to provide additional disaggregated disclosures regarding certain categories of expenses included in relevant income statement expense captions. The amendments are effective for annual reporting periods beginning after December 15, 2026, and for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of these amendments may have on its consolidated financial statements and related disclosures.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In December 2025, the FASB issued ASU 2025-12, Codification Improvements, which makes amendments to various Topics in the FASB Accounting Standards Codification to clarify guidance, correct unintended applications, and make other incremental improvements to U.S. GAAP. The amendments are effective for all entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2025-12 on its consolidated financial statements and related disclosures.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Except as discussed above, the Company does not believe that other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="cref_1268430831" id="ixv-7148">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(a)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Basis of Presentation&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="cref_1268430831" id="ixv-7158">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(b)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Principles of Consolidation&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The consolidated financial statements include the financial statements of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Subsidiaries are consolidated from the date the Company obtains control and cease to be consolidated from the date the Company loses control. The results of operations of subsidiaries disposed of during the year presented are included in the consolidated financial statements through the respective dates on which control ceased, as applicable.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock contextRef="cref_1268430831" id="ixv-7170">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(c)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Discontinued Operations&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company reports a disposal of a component or group of components as discontinued operations when the disposal represents a strategic shift that has, or will have, a major effect on the Company&#x2019;s operations and financial results. The results of operations of a component classified as discontinued operations are presented separately from continuing operations in the consolidated statements of operations and comprehensive income (loss) for all periods presented. Cash flows attributable to discontinued operations are separately presented in the consolidated statements of cash flows.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="cref_1268430831" id="ixv-7192">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(d)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Use of Estimates&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of income and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Significant estimates and assumptions reflected in the Company&#x2019;s consolidated financial statements include, but are not limited to, allowance for expected credit losses, stock-based compensation, interest rate of lease and gain on disposal of subsidiaries.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="cref_1268430831" id="ixv-7204">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(e)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Cash&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Cash consists of cash on hand and demand deposits with financial institutions that are unrestricted as to withdrawal and use.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company maintains its cash with financial institutions that management believes to be of high credit quality. The Company monitors the financial condition of these institutions and has not experienced any losses on such accounts.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="cref_1268430831" id="ixv-7216">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(f)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Foreign Currency Translation and Transactions&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The accompanying consolidated financial statements are presented in U.S. dollars (&#x201c;US$&#x201d;), which is the reporting currency of the Company. The functional currency of the Company is the U.S. dollar. The functional currency of Acellent, the Company&#x2019;s Hong Kong subsidiary acquired in April 2026, is the Hong Kong dollar (&#x201c;HKD&#x201d;). Certain subsidiaries included in the consolidated financial statements prior to their dispositions during the year ended June 30, 2026 also used currencies other than the U.S. dollar as their functional currencies.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Assets and liabilities of subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars at the exchange rates in effect at the balance sheet date. Revenues and expenses are translated at the exchange rates in effect on the dates of the transactions or, when appropriate, at average exchange rates for the applicable reporting period. Translation adjustments resulting from the translation of the financial statements of foreign subsidiaries are recorded in other comprehensive income (loss) and accumulated in accumulated other comprehensive income, a component of stockholders&#x2019; equity.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Transactions denominated in currencies other than an entity&#x2019;s functional currency are initially recorded at the exchange rate in effect on the transaction date. Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured at the exchange rate in effect at the balance sheet date, and resulting foreign currency transaction gains or losses are recognized in the consolidated statements of operations and comprehensive income (loss).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;       &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The following table sets forth the exchange rates used in preparing the accompanying consolidated financial statements:&lt;/p&gt;  &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;June 30, &lt;br/&gt;     2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;June 30, &lt;br/&gt;     2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: justify;"&gt;US$ to NT$ fiscal year-end rate&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;31.8500&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;29.1800&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;US$ to NT$ average rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;31.0413&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;32.0919&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify;"&gt;US$ to HKD fiscal year-end rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.8420&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.8500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;US$ to HKD average rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.8347&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.7900&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock contextRef="cref_1268430831" id="ixv-7237">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The following table sets forth the exchange rates used in preparing the accompanying consolidated financial statements:&lt;/p&gt;  &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;June 30, &lt;br/&gt;     2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;June 30, &lt;br/&gt;     2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: justify;"&gt;US$ to NT$ fiscal year-end rate&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;31.8500&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;29.1800&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;US$ to NT$ average rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;31.0413&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;32.0919&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify;"&gt;US$ to HKD fiscal year-end rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.8420&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.8500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;US$ to HKD average rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.8347&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.7900&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="cref_1798085713"
      decimals="4"
      id="ixv-12172"
      unitRef="uref_1766841203">31.85</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="cref_1974873320"
      decimals="4"
      id="ixv-12173"
      unitRef="uref_1766841203">29.18</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <advb:PeriodAverageExchangeRates
      contextRef="cref_1616045213"
      decimals="4"
      id="ixv-12174"
      unitRef="uref_1766841203">31.0413</advb:PeriodAverageExchangeRates>
    <advb:PeriodAverageExchangeRates
      contextRef="cref_2121645178"
      decimals="4"
      id="ixv-12175"
      unitRef="uref_1766841203">32.0919</advb:PeriodAverageExchangeRates>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="cref_829090450"
      decimals="4"
      id="ixv-12176"
      unitRef="uref_1766841203">7.842</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="cref_270933567"
      decimals="4"
      id="ixv-12177"
      unitRef="uref_1766841203">7.85</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <advb:PeriodAverageExchangeRates
      contextRef="cref_1632848432"
      decimals="4"
      id="ixv-12178"
      unitRef="uref_1766841203">7.8347</advb:PeriodAverageExchangeRates>
    <advb:PeriodAverageExchangeRates
      contextRef="cref_1606981235"
      decimals="4"
      id="ixv-12179"
      unitRef="uref_1766841203">7.79</advb:PeriodAverageExchangeRates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="cref_1268430831" id="ixv-7302">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(g)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Fair Value Measurements&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company follows ASC 820, Fair Value Measurement, which defines fair value, establishes a framework for measuring fair value and establishes a fair value hierarchy that prioritizes the inputs used in valuation techniques. The three levels of the fair value hierarchy are as follows:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Level 1 &#x2014; Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Level 2 &#x2014; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&#x25cf;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Level 3 &#x2014; Unobservable inputs for the asset or liability that are significant to the fair value measurement.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The classification of a fair value measurement within the hierarchy is based on the lowest level input that is significant to the measurement.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The carrying amounts of the Company&#x2019;s short-term financial assets and liabilities approximate their fair values because of the short-term nature of these instruments.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <advb:RelatedPartiesPolicyTextBlock contextRef="cref_1268430831" id="ixv-7337">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(h)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Related Parties&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company identifies related parties and accounts for and discloses related-party transactions in accordance with ASC 850, Related Party Disclosures. Related parties generally include the Company&#x2019;s directors and executive officers, principal stockholders, their immediate family members, and entities that are controlled by or under common control with such parties.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Transactions with related parties are recorded based on the terms of the underlying arrangements. Material related-party transactions and balances are disclosed in the accompanying consolidated financial statements.&lt;/p&gt;</advb:RelatedPartiesPolicyTextBlock>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock contextRef="cref_1268430831" id="ixv-7349">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(i)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Credit Losses&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company accounts for credit losses on financial assets measured at amortized cost in accordance with ASC 326, &lt;i&gt;Financial Instruments &#x2014; Credit Losses&lt;/i&gt;. The Company estimates expected credit losses based on relevant information available about past events, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amounts.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company evaluates amount due from related parties and other applicable financial assets for expected credit losses on an individual or collective basis, as appropriate, considering factors such as historical payment experience, the financial condition and creditworthiness of the counterparties, the aging and nature of the outstanding balances, current economic conditions, and reasonable and supportable forecasts of future economic conditions.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;An allowance for credit losses is recorded as a reduction of the carrying amount of the related financial asset, with the corresponding credit loss expense recognized in the consolidated statements of operations and comprehensive income (loss). Financial assets are written off against the allowance when they are deemed uncollectible. Recoveries of amounts previously written off are recognized when received.&lt;/p&gt;</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="cref_1268430831" id="ixv-7370">  &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(j)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Revenue Recognition&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company recognizes revenue in accordance with ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;. Revenue is recognized when control of the promised services is transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those services.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company recognizes revenue in accordance with ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;. The five-step model defined by ASC 606 requires the Company to (1) identify its contracts with customers, (2) identify its performance obligations under those contracts, (3) determine the transaction prices of those contracts, (4) allocate the transaction prices to its performance obligations in those contracts, and (5) recognize revenue when each performance obligation under those contracts is satisfied.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;A contract contains a promise (or promises) to transfer goods or services to a customer. A performance obligation is a promise (or a group of promises) that is distinct. The transaction price is the amount of consideration a company expects to be entitled from a customer in exchange for providing the goods or services.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company enters into a distinct contract with its customers for the provision of agency service.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Transaction price is the amount of consideration in the contract to which the Company expects to be entitled in exchange for transferring the promised goods or services. The transaction price is fixed. The agency fee was one-off, non-refundable right for the agent sourcing customers for the Company.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Revenue is recognized when the Company satisfies a performance obligation by transferring the promised service to a customer, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for that service.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company&#x2019;s revenue from continuing operations is primarily derived from agency services provided through its subsidiary, Acellent. The Company identifies the services promised under each customer arrangement and recognizes the related agency fee when the applicable performance obligation has been satisfied in accordance with the terms of that arrangement (point in time).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Revenue from contracts with customers consisted of the following:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-weight: bold;"&gt;Revenue by major source&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;Year ended &lt;br/&gt; June 30, &lt;br/&gt; 2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;Year ended &lt;br/&gt; June 30, &lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt;"&gt;Agency fee revenue &#x2013; point in time&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;127,637&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_289217852;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;Total revenue&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;127,637&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_64957701;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="cref_1268430831" id="ixv-7396">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Revenue from contracts with customers consisted of the following:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-weight: bold;"&gt;Revenue by major source&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;Year ended &lt;br/&gt; June 30, &lt;br/&gt; 2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;Year ended &lt;br/&gt; June 30, &lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt;"&gt;Agency fee revenue &#x2013; point in time&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;127,637&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_289217852;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;Total revenue&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;127,637&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_64957701;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_227132498"
      decimals="0"
      id="ixv-12180"
      unitRef="uref_518000893">127637</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12181"
      unitRef="uref_518000893">127637</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="cref_1268430831" id="ixv-7451">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(k)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Stock-Based Compensation&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company measures stock-based compensation at the fair value of the equity instruments issued and recognizes the resulting expense over the period in which the related services are received under ASC 718. Stock-based compensation expense is included in operating expenses in the consolidated statements of operations and comprehensive income (loss).&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="cref_1268430831" id="ixv-7467">  &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(l)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Impairment of Long-Lived Assets&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company reviews its long-lived assets, including finite-lived intangible assets and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;When indicators of impairment exist, recoverability is assessed by comparing the carrying amount of the asset or asset group to the estimated undiscounted future cash flows expected to result from its use and eventual disposition. If the carrying amount is not recoverable, an impairment loss is recognized for the amount by which the carrying amount exceeds its fair value. Fair value is determined using appropriate valuation techniques based on the facts and circumstances.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="cref_1268430831" id="ixv-7481">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(m)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Commitments and Contingencies&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company is subject to commitments and contingencies arising in the ordinary course of business, including legal proceedings, claims, contractual commitments and other matters. The Company records an accrual for a loss contingency when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. If a loss is reasonably possible but not probable, or if a loss is probable but the amount cannot be reasonably estimated, the nature of the contingency and an estimate of the possible loss or range of loss, if estimable, are disclosed in the notes to the consolidated financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company evaluates its commitments and contingencies based on the facts and circumstances available at each reporting date and revises its estimates as additional information becomes available.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="cref_1268430831" id="ixv-7493">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(n)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Income Taxes&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company accounts for income taxes in accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards, if any. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;A valuation allowance is established against deferred tax assets when, based on the weight of available positive and negative evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluates the realizability of its deferred tax assets at each reporting date and adjusts the valuation allowance, as necessary, based on changes in facts and circumstances.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The Company recognizes the effect of uncertain tax positions when it is more likely than not, based on the technical merits, that the tax position will be sustained upon examination by the relevant taxing authority. A tax position that meets the recognition threshold is measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement contextRef="cref_1268430831" id="ixv-12182">A tax position that meets the recognition threshold is measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement.</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="cref_1268430831" id="ixv-7510">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(o)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Earnings (Loss) Per Share&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Basic earnings (loss) per share is computed by dividing income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Diluted earnings (loss) per share is computed by dividing income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for the effect of potentially dilutive securities, if any. Potential common shares are excluded from the computation of diluted earnings (loss) per share when their effect would be anti-dilutive.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Basic and diluted earnings (loss) per share from continuing operations and discontinued operations are presented separately in accordance with U.S. GAAP.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;All share and per-share amounts presented in the accompanying consolidated financial statements have been retrospectively adjusted, as applicable, to reflect the reverse stock split described below.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="cref_1268430831" id="ixv-7532">  &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(p)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Comprehensive Income (Loss)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) includes foreign currency translation adjustments arising from the translation of the financial statements of foreign subsidiaries whose functional currencies are other than the U.S. dollar.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Foreign currency translation adjustments are reported as a component of other comprehensive income (loss), and the cumulative amount is reported in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="cref_1268430831" id="ixv-7546">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(q)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Segment Reporting&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company determines its operating segments in accordance with ASC 280, Segment Reporting, based on the manner in which the chief operating decision maker (&#x201c;CODM&#x201d;) manages the Company and evaluates operating performance. Operating segments are components of an enterprise for which separate financial information is available and is regularly evaluated by the CODM in deciding how to allocate resources and assess performance.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The Company has one reportable segment for its continuing operations, consisting primarily of its technology and software-related operations. The Company&#x2019;s historical biotechnology operations, which were disposed of during the year ended June 30, 2026, are presented as discontinued operations and are not included in the Company&#x2019;s continuing reportable segment. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12183"
      unitRef="uref_345177085">1</us-gaap:NumberOfReportableSegments>
    <advb:ReverseStockSplitPolicyTextBlock contextRef="cref_1268430831" id="fc_1956178127">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(r)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Reverse Stock Split&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; On February 20, 2026, the Company effected a 1-for-20 reverse stock split of its common stock. The reverse stock split reduced the number of issued and outstanding shares of common stock on a proportionate basis and did not change the par value per share of the Company&#x2019;s common stock. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;All share and per-share amounts presented in the accompanying consolidated financial statements and related notes have been retrospectively adjusted, as applicable, to reflect the reverse stock split for all periods presented.&lt;/p&gt;</advb:ReverseStockSplitPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="cref_66595141" id="ixv-12184">1-for-20</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="cref_1268430831" id="ixv-7570">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;(s)&lt;/td&gt; &lt;td style="text-align: justify;"&gt;Recent Accounting Pronouncements&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In October 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-06, Disclosure Improvements &#x2014; Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative. The amendments incorporate certain disclosure and presentation requirements previously contained in SEC regulations into the FASB Accounting Standards Codification. For entities subject to the SEC&#x2019;s existing disclosure requirements, the effective date for each amendment will be the date on which the SEC removes the related disclosure requirement from its rules. The Company does not expect the adoption of ASU 2023-06 to have a material impact on its consolidated financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) &#x2014; Improvements to Income Tax Disclosures, which enhances income tax disclosures, primarily related to the rate reconciliation and income taxes paid. The amendments are effective for public business entities for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09 during the year ended June 30, 2026. The adoption did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In March 2024, the FASB issued ASU 2024-01, Compensation &#x2014; Stock Compensation (Topic 718) &#x2014; Scope Application of Profits Interest and Similar Awards. The amendments provide illustrative guidance to assist entities in determining whether profits interest and similar awards should be accounted for as share-based payment arrangements under ASC Topic 718. The amendments are effective for public business entities for annual periods beginning after December 15, 2024, including interim periods within those annual periods. The Company adopted ASU 2024-01 during the year ended June 30, 2026. The adoption did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In March 2024, the FASB issued ASU 2024-02, Codification Improvements &#x2014; Amendments to Remove References to the Concepts Statements. The amendments remove references to various FASB Concepts Statements from the Codification and make other conforming amendments. The amendments are effective for public business entities for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. The Company adopted ASU 2024-02 during the year ended June 30, 2026. The adoption did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. In January 2025, the FASB issued ASU 2025-01, Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarifies the effective date of ASU 2024-03 for entities with non-calendar year ends. The amendments require public business entities to provide additional disaggregated disclosures regarding certain categories of expenses included in relevant income statement expense captions. The amendments are effective for annual reporting periods beginning after December 15, 2026, and for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of these amendments may have on its consolidated financial statements and related disclosures.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In December 2025, the FASB issued ASU 2025-12, Codification Improvements, which makes amendments to various Topics in the FASB Accounting Standards Codification to clarify guidance, correct unintended applications, and make other incremental improvements to U.S. GAAP. The amendments are effective for all entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2025-12 on its consolidated financial statements and related disclosures.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Except as discussed above, the Company does not believe that other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="cref_1268430831" id="ixv-7600">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;4.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;ACQUISITION OF ACELLENT&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; On April 2, 2026, the Company and an independent individual entered into a sale and purchase agreement that the Company agreed to acquire 100% of the equity interests in Acellent. In connection with the transaction, the Company issued 270,000 shares of common stock of the Company as a consideration of acquiring the 100% equity interest in Acellent and compensation to the seller to accept the position as director and CEO of the Company. As of the date of acquisition, the financial statements of Acellent only consisted of cash of $12,891 without other assets and there were no operations and no profit generation. As a result, the acquisition of Acellent was treated as acquisition of asset, i.e. the cash. The issue of common stock serves two purposes, (i) acquisition of entire equity interest of Acellent; and (ii) as compensation to current seller for accepting the position of CEO and director of the Company after the acquisition. The fair value of common stock of the Company amounting to US$1,746,900 as the date of acquisition was divided into two parts, $12,891 was treated as acquisition of Acellent with equivalent to fair value of only asset, i.e. cash, acquired in Acellent and the remaining part of $1,734,009 was treated as stock-based compensation to the director based on ASC 718. The stock-based compensation was charged to statements of operations fully for the year ended June 30, 2026 since based on the agreement with the seller, there were no vesting period, no options, no service conditions and were awarded the common stock of the Company to the seller directly upon transferred of shares on April 23, 2026. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The results of operations of Acellent have been included in the Company&#x2019;s consolidated financial statements from the accounting acquisition date. For the year ended June 30, 2026, the Company&#x2019;s revenue generated by Acellent was $127,637 and net loss incurred by Acellent which was consolidated was $13,406. &lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="cref_811874486"
      decimals="2"
      id="ixv-12185"
      unitRef="uref_1766841203">1</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="cref_343760561"
      decimals="0"
      id="ixv-12186"
      unitRef="uref_1493501123">270000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="cref_518123335"
      decimals="2"
      id="ixv-12187"
      unitRef="uref_1766841203">1</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="cref_1539055106"
      decimals="0"
      id="ixv-12188"
      unitRef="uref_518000893">12891</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <advb:FairValueOfCommonStock
      contextRef="cref_512039560"
      decimals="0"
      id="ixv-12189"
      unitRef="uref_518000893">1746900</advb:FairValueOfCommonStock>
    <advb:FairValueOfCashAcquired
      contextRef="cref_512039560"
      decimals="0"
      id="ixv-12190"
      unitRef="uref_518000893">12891</advb:FairValueOfCashAcquired>
    <advb:FairValueOfStockBasedCompensation
      contextRef="cref_512039560"
      decimals="0"
      id="ixv-12191"
      unitRef="uref_518000893">1734009</advb:FairValueOfStockBasedCompensation>
    <us-gaap:Revenues
      contextRef="cref_1733049814"
      decimals="0"
      id="ixv-12192"
      unitRef="uref_518000893">127637</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1733049814"
      decimals="0"
      id="ixv-12193"
      unitRef="uref_518000893">13406</us-gaap:NetIncomeLoss>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="cref_1268430831" id="ixv-7612">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;5.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;DISCONTINUED OPERATIONS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;During the fiscal year ended June 30, 2026, the Company completed the dispositions of its historical biotechnology operations as part of its strategic restructuring and transition toward artificial intelligence and financial algorithmic software-related businesses. The Company determined that these dispositions represented a strategic shift that had a major effect on the Company&#x2019;s operations and financial results. Accordingly, the results of these historical biotechnology operations have been presented as discontinued operations for all periods presented in accordance with ASC 205-20, &lt;i&gt;Presentation of Financial Statements &#x2014; Discontinued Operations.&lt;/i&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;       &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; On December 23, 2025, the Company entered into a sale and purchase agreement with an independent individual, Wei Ha Hui, pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed HK Limited, a Hong Kong company and a wholly owned subsidiary of the Company (the &#x201c;Hong Kong Subsidiary&#x201d;), for an aggregate agreed cash purchase price of $23,000, subject to the terms and conditions set forth in the agreement. All intellectual property owned by the Hong Kong subsidiary, including intellectual property owned by Shanghai Sglcell Biotech Co., Ltd., a wholly owned subsidiary of the Hong Kong subsidiary, was transferred to the buyer at the closing of this transaction on December 31, 2025. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; On June 30, 2026, the Company entered into a sale and purchase agreement with an independent individual, Miaozhu Zhao, pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed Inc. (Taiwan), a Taiwan company and a wholly owned subsidiary of the Company (the &#x201c;Taiwan Subsidiary&#x201d;), for an aggregate cash purchase price of $490,000 based on a valuation report commissioned by the Company, subject to the terms and conditions set forth in the Agreement. All intellectual property owned by the Taiwan subsidiary was transferred to the buyer at the closing of this transaction on June 30, 2026. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The subsidiary comprises our market development and clinical-related business operating segment. As a result of the planned disposition of the subsidiaries, the market development and clinical-related business operating segment meets the held for sale criteria of ASC 205-20. Accordingly, the historical results of operations of the market development and clinical-related business operating segment has been reflected as discontinued operations in our consolidated financial statement for all periods prior to the agreements on December 23, 2025 and June 30, 2026, respectively.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; As a result, the Hong Kong Subsidiary completed during the period ended December 31, 2025, the Company deconsolidated the subsidiary as of December 31, 2025 while the Taiwan Subsidiary completed during the period ended June 30, 2026, the Company deconsolidated the subsidiary as of June 30, 2026. Therefore, the Company reported no assets or liabilities of the subsidiaries from the date of disposals and recognized a net gain on deconsolidation of $14,015,417, which has been reflected as a component of discounted operations, net of tax on the accompanying consolidated statements of operations and comprehensive income (loss). &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Income from discontinued operations, net of tax, was $12,938,353 for the year ended June 30, 2026 and loss from discontinued operations, net of tax, was $2,172,499 for the year ended June 30, 2025. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-weight: bold;"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;The assets and liabilities of disposal entities as of the respective date of disposal were as follows: &lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Hong Kong Subsidiary&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Taiwan Subsidiary&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;As of&lt;br/&gt; December&#160;31,&lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;As of&lt;br/&gt;  June 30,&lt;br/&gt;  2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Net assets disposal of:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%;"&gt;Cash&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;5,926&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2,598,924&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Due from Advanced Biomed Inc. (Taiwan)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;438,720&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2120331561;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Prepaid expenses and other current assets, net&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;889,055&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;49,989&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Equipment, net&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;155,270&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;97,023&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Right-of-use assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1695365751;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;32,432&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Other non-current assets, net&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;214,497&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1804957200;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Accounts payable, accruals, and other current liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(299,904&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(397,101&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Lease liabilities (current and non-current)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1282026241;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(32,432&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Due to the Company&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(6,432,919&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(8,602,603&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Due to related parties of Hong Kong Subsidiary&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(163,706&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2142985455;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Due to Hong Kong Subsidiary&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_338277775;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(661,516&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Due to related parties of Taiwan Subsidiary&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_335351225;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(514,123&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Tax payable&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(180&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_948391774;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt;"&gt;Total net liabilities disposed of&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(5,193,241&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(7,429,407&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Hong Kong Subsidiary&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Taiwan Subsidiary&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#x3000;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#x3000;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#x3000;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#x3000;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Gain on disposal of subsidiaries:&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;&#x3000;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;&#x3000;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;&#x3000;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; width: 64%; text-align: left;"&gt;Total net liabilities disposed of&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;5,193,241&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;7,429,407&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;12,622,648&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Release of the translation of subsidiaries in foreign currency charged to other comprehensive loss in prior periods&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;450,526&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;429,243&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;879,769&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Cash consideration&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;23,000&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;490,000&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;513,000&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;5,666,767&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;8,348,650&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;14,015,417&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;Net cash inflow (outflow) arising from disposal&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Cash consideration received during the year&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;23,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_189817666;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;23,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt;"&gt;Cash disposed of&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(5,926&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(2,598,924&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(2,604,850&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;17,074&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(2,598,924&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(2,581,850&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-weight: bold;"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;Summary of Assets and Liabilities of Discontinued Operations&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The major classes of assets and liabilities of discontinued operation included in the consolidated balance sheets as of June 30, 2026 and 2025 were as follows:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-weight: bold;"&gt;As of&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-weight: bold;"&gt;As of&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;June 30, &lt;br/&gt; 2026&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;June 30, &lt;br/&gt; 2025&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Current assets:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; width: 76%;"&gt;Cash&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1606802807;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2,872,776&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Prepaid expenses and other current assets, net&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_309314987;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,290,951&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total current assets of discontinued operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1181372779;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,163,727&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;Non-current assets:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Equipment, net&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1105684479;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;331,346&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Right-of-use assets, net&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1908456561;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;65,399&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Other non-current assets, net&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1108096154;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;83,027&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total non-current assets of discontinued operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1140262525;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;479,772&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt;"&gt;Total assets of discontinued operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1488126211;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;4,643,499&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="font-weight: bold;"&gt;Liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;Current liabilities:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Accounts payable, accruals, and other current liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_731755198;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,072,486&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Amounts due to the Company&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_939041857;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;16,349,752&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Current lease payable&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1271090401;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;35,811&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total current liabilities of discontinued operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1387464487;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;18,458,049&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;Non-current liabilities:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Non-current lease payable&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1711824719;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,879&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Amount due to related parties &#x2013; non-current&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1349873447;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;69,797&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total non-current liabilities of discontinued operations&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;75,676&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt;"&gt;Total liabilities of discontinued operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_220337250;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;18,533,725&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;       &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; As of June 30, 2025, the consolidated balance sheet of the Company separately presented $16,349,752 as due from discontinued operations. The liabilities of discontinued operations presented above included a corresponding $16,349,752 due to the Company. These balances arose from transactions between the parent company and the operations subsequently disposed of and are separate from amounts due to external related parties discussed in Note 11. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-weight: bold;"&gt;(c)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;Summary of Results of Discontinued Operations&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The major components of the results of discontinued operations included in the consolidated statements of operations and comprehensive income (loss) for the years ended June 30, 2026 and 2025 were as follows:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;For the Year Ended &lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Operating expenses:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; padding-left: 9pt;"&gt;Research and development expenses&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;869,823&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;909,771&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;General and administrative expenses&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;443,126&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,024,795&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Total operating expenses&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,312,949&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,934,566&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Operating loss&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(1,312,949&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(1,934,566&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;Other income (expense):&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-left: 9pt;"&gt;Interest income&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;457&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;24,915&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Other income (expense), net&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;235,428&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(262,848&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Total other income (expense), net&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;235,885&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(237,933&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;Loss before tax expense&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(1,077,064&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(2,172,499&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Income tax expense&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1778345013;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_53216848;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;Loss incurred in discontinued operations&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(1,077,064&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(2,172,499&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Gain on disposal of subsidiaries, net of tax&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;14,015,417&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1785573186;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt;"&gt;Net income from discounted operations, net of tax&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;12,938,353&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(2,172,499&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <advb:PercentageOfIssuedAndOutstandingShares
      contextRef="cref_677513081"
      decimals="2"
      id="ixv-12194"
      unitRef="uref_1766841203">1</advb:PercentageOfIssuedAndOutstandingShares>
    <us-gaap:SupplementalDeferredPurchasePrice
      contextRef="cref_677513081"
      decimals="0"
      id="ixv-12195"
      unitRef="uref_518000893">23000</us-gaap:SupplementalDeferredPurchasePrice>
    <advb:PercentageOfIssuedAndOutstandingShares
      contextRef="cref_1622985829"
      decimals="2"
      id="ixv-12196"
      unitRef="uref_1766841203">1</advb:PercentageOfIssuedAndOutstandingShares>
    <us-gaap:SupplementalDeferredPurchasePrice
      contextRef="cref_1622985829"
      decimals="0"
      id="ixv-12197"
      unitRef="uref_518000893">490000</us-gaap:SupplementalDeferredPurchasePrice>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="cref_1622985829"
      decimals="0"
      id="ixv-12198"
      unitRef="uref_518000893">14015417</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12199"
      unitRef="uref_518000893">12938353</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12200"
      unitRef="uref_518000893">-2172499</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="cref_1268430831" id="ixv-7648">&lt;span style="font-weight: bold;"&gt;The assets and liabilities of disposal entities as of the respective date of disposal were as follows: &lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Hong Kong Subsidiary&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Taiwan Subsidiary&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;As of&lt;br/&gt; December&#160;31,&lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;As of&lt;br/&gt;  June 30,&lt;br/&gt;  2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Net assets disposal of:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%;"&gt;Cash&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;5,926&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2,598,924&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Due from Advanced Biomed Inc. (Taiwan)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;438,720&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2120331561;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Prepaid expenses and other current assets, net&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;889,055&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;49,989&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Equipment, net&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;155,270&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;97,023&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Right-of-use assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1695365751;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;32,432&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Other non-current assets, net&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;214,497&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1804957200;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Accounts payable, accruals, and other current liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(299,904&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(397,101&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Lease liabilities (current and non-current)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1282026241;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(32,432&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Due to the Company&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(6,432,919&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(8,602,603&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Due to related parties of Hong Kong Subsidiary&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(163,706&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2142985455;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Due to Hong Kong Subsidiary&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_338277775;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(661,516&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Due to related parties of Taiwan Subsidiary&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_335351225;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(514,123&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Tax payable&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(180&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_948391774;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt;"&gt;Total net liabilities disposed of&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(5,193,241&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(7,429,407&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Hong Kong Subsidiary&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Taiwan Subsidiary&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#x3000;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#x3000;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#x3000;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#x3000;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Gain on disposal of subsidiaries:&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;&#x3000;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;&#x3000;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;&#x3000;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; width: 64%; text-align: left;"&gt;Total net liabilities disposed of&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;5,193,241&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;7,429,407&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;12,622,648&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Release of the translation of subsidiaries in foreign currency charged to other comprehensive loss in prior periods&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;450,526&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;429,243&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;879,769&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Cash consideration&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;23,000&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;490,000&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;513,000&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;5,666,767&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;8,348,650&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;14,015,417&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;Net cash inflow (outflow) arising from disposal&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Cash consideration received during the year&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;23,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_189817666;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;23,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt;"&gt;Cash disposed of&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(5,926&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(2,598,924&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(2,604,850&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;17,074&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(2,598,924&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(2,581,850&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The major classes of assets and liabilities of discontinued operation included in the consolidated balance sheets as of June 30, 2026 and 2025 were as follows:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-weight: bold;"&gt;As of&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-weight: bold;"&gt;As of&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;June 30, &lt;br/&gt; 2026&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;June 30, &lt;br/&gt; 2025&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Current assets:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; width: 76%;"&gt;Cash&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1606802807;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2,872,776&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Prepaid expenses and other current assets, net&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_309314987;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,290,951&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total current assets of discontinued operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1181372779;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,163,727&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;Non-current assets:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Equipment, net&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1105684479;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;331,346&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Right-of-use assets, net&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1908456561;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;65,399&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Other non-current assets, net&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1108096154;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;83,027&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total non-current assets of discontinued operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1140262525;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;479,772&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt;"&gt;Total assets of discontinued operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1488126211;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;4,643,499&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="font-weight: bold;"&gt;Liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;Current liabilities:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Accounts payable, accruals, and other current liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_731755198;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,072,486&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Amounts due to the Company&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_939041857;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;16,349,752&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Current lease payable&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1271090401;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;35,811&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total current liabilities of discontinued operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1387464487;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;18,458,049&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;Non-current liabilities:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Non-current lease payable&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1711824719;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,879&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Amount due to related parties &#x2013; non-current&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1349873447;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;69,797&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total non-current liabilities of discontinued operations&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;75,676&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt;"&gt;Total liabilities of discontinued operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_220337250;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;18,533,725&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The major components of the results of discontinued operations included in the consolidated statements of operations and comprehensive income (loss) for the years ended June 30, 2026 and 2025 were as follows:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;For the Year Ended &lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Operating expenses:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; padding-left: 9pt;"&gt;Research and development expenses&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;869,823&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;909,771&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;General and administrative expenses&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;443,126&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,024,795&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Total operating expenses&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,312,949&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,934,566&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Operating loss&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(1,312,949&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(1,934,566&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;Other income (expense):&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-left: 9pt;"&gt;Interest income&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;457&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;24,915&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Other income (expense), net&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;235,428&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(262,848&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Total other income (expense), net&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;235,885&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(237,933&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;Loss before tax expense&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(1,077,064&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(2,172,499&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Income tax expense&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1778345013;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_53216848;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;Loss incurred in discontinued operations&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(1,077,064&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(2,172,499&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Gain on disposal of subsidiaries, net of tax&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;14,015,417&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1785573186;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt;"&gt;Net income from discounted operations, net of tax&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;12,938,353&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(2,172,499&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCash
      contextRef="cref_1234264462"
      decimals="0"
      id="ixv-12201"
      unitRef="uref_518000893">5926</us-gaap:DisposalGroupIncludingDiscontinuedOperationCash>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCash
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12202"
      unitRef="uref_518000893">2598924</us-gaap:DisposalGroupIncludingDiscontinuedOperationCash>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="cref_1234264462"
      decimals="0"
      id="ixv-12203"
      unitRef="uref_518000893">438720</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets
      contextRef="cref_1234264462"
      decimals="0"
      id="ixv-12204"
      unitRef="uref_518000893">889055</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12205"
      unitRef="uref_518000893">49989</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="cref_1234264462"
      decimals="0"
      id="ixv-12206"
      unitRef="uref_518000893">155270</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12207"
      unitRef="uref_518000893">97023</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12208"
      unitRef="uref_518000893">32432</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets
      contextRef="cref_1234264462"
      decimals="0"
      id="ixv-12209"
      unitRef="uref_518000893">214497</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <advb:DisposalGroupIncludingDiscontinuedOperationDisposedOfAccountsPayableAccrualsAndOtherCurrentLiabilities
      contextRef="cref_1234264462"
      decimals="0"
      id="fc_649721228"
      unitRef="uref_518000893">-299904</advb:DisposalGroupIncludingDiscontinuedOperationDisposedOfAccountsPayableAccrualsAndOtherCurrentLiabilities>
    <advb:DisposalGroupIncludingDiscontinuedOperationDisposedOfAccountsPayableAccrualsAndOtherCurrentLiabilities
      contextRef="cref_1380723918"
      decimals="0"
      id="fc_1898059153"
      unitRef="uref_518000893">-397101</advb:DisposalGroupIncludingDiscontinuedOperationDisposedOfAccountsPayableAccrualsAndOtherCurrentLiabilities>
    <advb:DisposalGroupIncludingDiscontinuedOperationLeaseLiabilities
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12212"
      unitRef="uref_518000893">-32432</advb:DisposalGroupIncludingDiscontinuedOperationLeaseLiabilities>
    <advb:DisposalGroupIncludingDiscontinuedOperationDueToTheCompany
      contextRef="cref_1234264462"
      decimals="0"
      id="ixv-12213"
      unitRef="uref_518000893">-6432919</advb:DisposalGroupIncludingDiscontinuedOperationDueToTheCompany>
    <advb:DisposalGroupIncludingDiscontinuedOperationDueToTheCompany
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12214"
      unitRef="uref_518000893">-8602603</advb:DisposalGroupIncludingDiscontinuedOperationDueToTheCompany>
    <advb:DisposalGroupIncludingDiscontinuedOperationDueToRelatedParties
      contextRef="cref_2109378812"
      decimals="0"
      id="ixv-12215"
      unitRef="uref_518000893">-163706</advb:DisposalGroupIncludingDiscontinuedOperationDueToRelatedParties>
    <advb:DisposalGroupIncludingDiscontinuedOperationDueToTheCompany
      contextRef="cref_890578433"
      decimals="0"
      id="ixv-12216"
      unitRef="uref_518000893">-661516</advb:DisposalGroupIncludingDiscontinuedOperationDueToTheCompany>
    <advb:DisposalGroupIncludingDiscontinuedOperationDueToRelatedParties
      contextRef="cref_944234346"
      decimals="0"
      id="ixv-12217"
      unitRef="uref_518000893">-514123</advb:DisposalGroupIncludingDiscontinuedOperationDueToRelatedParties>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxPayable
      contextRef="cref_1234264462"
      decimals="0"
      id="ixv-12218"
      unitRef="uref_518000893">180</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxPayable>
    <advb:DisposalGroupIncludingDiscontinuedOperationNetLiabilitiesDisposedOf
      contextRef="cref_1234264462"
      decimals="0"
      id="ixv-12219"
      unitRef="uref_518000893">-5193241</advb:DisposalGroupIncludingDiscontinuedOperationNetLiabilitiesDisposedOf>
    <advb:DisposalGroupIncludingDiscontinuedOperationNetLiabilitiesDisposedOf
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12220"
      unitRef="uref_518000893">-7429407</advb:DisposalGroupIncludingDiscontinuedOperationNetLiabilitiesDisposedOf>
    <advb:DisposalGroupIncludingDiscontinuedOperationTotalNetLiabilitiesDisposed
      contextRef="cref_2137941047"
      decimals="0"
      id="ixv-12221"
      unitRef="uref_518000893">5193241</advb:DisposalGroupIncludingDiscontinuedOperationTotalNetLiabilitiesDisposed>
    <advb:DisposalGroupIncludingDiscontinuedOperationTotalNetLiabilitiesDisposed
      contextRef="cref_809252632"
      decimals="0"
      id="ixv-12222"
      unitRef="uref_518000893">7429407</advb:DisposalGroupIncludingDiscontinuedOperationTotalNetLiabilitiesDisposed>
    <advb:DisposalGroupIncludingDiscontinuedOperationTotalNetLiabilitiesDisposed
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12223"
      unitRef="uref_518000893">12622648</advb:DisposalGroupIncludingDiscontinuedOperationTotalNetLiabilitiesDisposed>
    <advb:DisposalGroupIncludingDiscontinuedOperationOfForeignCurrencyTranslation
      contextRef="cref_2137941047"
      decimals="0"
      id="ixv-12224"
      unitRef="uref_518000893">450526</advb:DisposalGroupIncludingDiscontinuedOperationOfForeignCurrencyTranslation>
    <advb:DisposalGroupIncludingDiscontinuedOperationOfForeignCurrencyTranslation
      contextRef="cref_809252632"
      decimals="0"
      id="ixv-12225"
      unitRef="uref_518000893">429243</advb:DisposalGroupIncludingDiscontinuedOperationOfForeignCurrencyTranslation>
    <advb:DisposalGroupIncludingDiscontinuedOperationOfForeignCurrencyTranslation
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12226"
      unitRef="uref_518000893">879769</advb:DisposalGroupIncludingDiscontinuedOperationOfForeignCurrencyTranslation>
    <advb:DisposalGroupIncludingDiscontinuedOperationCashConsideration
      contextRef="cref_2137941047"
      decimals="0"
      id="ixv-12227"
      unitRef="uref_518000893">23000</advb:DisposalGroupIncludingDiscontinuedOperationCashConsideration>
    <advb:DisposalGroupIncludingDiscontinuedOperationCashConsideration
      contextRef="cref_809252632"
      decimals="0"
      id="ixv-12228"
      unitRef="uref_518000893">490000</advb:DisposalGroupIncludingDiscontinuedOperationCashConsideration>
    <advb:DisposalGroupIncludingDiscontinuedOperationCashConsideration
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12229"
      unitRef="uref_518000893">513000</advb:DisposalGroupIncludingDiscontinuedOperationCashConsideration>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="cref_2137941047"
      decimals="0"
      id="ixv-12230"
      unitRef="uref_518000893">5666767</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="cref_809252632"
      decimals="0"
      id="ixv-12231"
      unitRef="uref_518000893">8348650</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12232"
      unitRef="uref_518000893">14015417</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <advb:DiscontinuedOperationNetCashInflowOutflowArisingFromCashConsiderationReceived
      contextRef="cref_2137941047"
      decimals="0"
      id="ixv-12233"
      unitRef="uref_518000893">23000</advb:DiscontinuedOperationNetCashInflowOutflowArisingFromCashConsiderationReceived>
    <advb:DiscontinuedOperationNetCashInflowOutflowArisingFromCashConsiderationReceived
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12234"
      unitRef="uref_518000893">23000</advb:DiscontinuedOperationNetCashInflowOutflowArisingFromCashConsiderationReceived>
    <advb:DiscontinuedOperationNetCashInflowOutflowArisingCashDisposedOf
      contextRef="cref_2137941047"
      decimals="0"
      id="ixv-12235"
      unitRef="uref_518000893">-5926</advb:DiscontinuedOperationNetCashInflowOutflowArisingCashDisposedOf>
    <advb:DiscontinuedOperationNetCashInflowOutflowArisingCashDisposedOf
      contextRef="cref_809252632"
      decimals="0"
      id="ixv-12236"
      unitRef="uref_518000893">-2598924</advb:DiscontinuedOperationNetCashInflowOutflowArisingCashDisposedOf>
    <advb:DiscontinuedOperationNetCashInflowOutflowArisingCashDisposedOf
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12237"
      unitRef="uref_518000893">-2604850</advb:DiscontinuedOperationNetCashInflowOutflowArisingCashDisposedOf>
    <advb:DiscontinuedOperationNetCashInflowOutflowArisingFromDisposal
      contextRef="cref_2137941047"
      decimals="0"
      id="fc_2137941047"
      unitRef="uref_518000893">17074</advb:DiscontinuedOperationNetCashInflowOutflowArisingFromDisposal>
    <advb:DiscontinuedOperationNetCashInflowOutflowArisingFromDisposal
      contextRef="cref_809252632"
      decimals="0"
      id="fc_809252632"
      unitRef="uref_518000893">-2598924</advb:DiscontinuedOperationNetCashInflowOutflowArisingFromDisposal>
    <advb:DiscontinuedOperationNetCashInflowOutflowArisingFromDisposal
      contextRef="cref_1268430831"
      decimals="0"
      id="fc_416647172"
      unitRef="uref_518000893">-2581850</advb:DiscontinuedOperationNetCashInflowOutflowArisingFromDisposal>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12241"
      unitRef="uref_518000893">2872776</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12242"
      unitRef="uref_518000893">1290951</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12243"
      unitRef="uref_518000893">4163727</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12244"
      unitRef="uref_518000893">331346</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <advb:DisposalGroupIncludingDiscontinuedOperationRightofuseAssetsNet
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12245"
      unitRef="uref_518000893">65399</advb:DisposalGroupIncludingDiscontinuedOperationRightofuseAssetsNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12246"
      unitRef="uref_518000893">83027</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12247"
      unitRef="uref_518000893">479772</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12248"
      unitRef="uref_518000893">4643499</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12249"
      unitRef="uref_518000893">2072486</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent>
    <advb:DisposalGroupIncludingDiscontinuedOperationLiabilitiesAmountDueToTheCompanyCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="fc_1739704296"
      unitRef="uref_518000893">16349752</advb:DisposalGroupIncludingDiscontinuedOperationLiabilitiesAmountDueToTheCompanyCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="cref_1096537008"
      decimals="0"
      id="fc_753648762"
      unitRef="uref_518000893">35811</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12252"
      unitRef="uref_518000893">18458049</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12253"
      unitRef="uref_518000893">5879</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <advb:DisposalGroupIncludingDiscontinuedOperationLiabilitiesNoncurrentAmountDuetoRelatedPartiesNonCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12254"
      unitRef="uref_518000893">69797</advb:DisposalGroupIncludingDiscontinuedOperationLiabilitiesNoncurrentAmountDuetoRelatedPartiesNonCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12255"
      unitRef="uref_518000893">75676</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12256"
      unitRef="uref_518000893">18533725</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <advb:DueFromDiscontinuedOperations
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12257"
      unitRef="uref_518000893">16349752</advb:DueFromDiscontinuedOperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12258"
      unitRef="uref_518000893">16349752</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
    <advb:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpenses
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12259"
      unitRef="uref_518000893">869823</advb:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpenses>
    <advb:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpenses
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12260"
      unitRef="uref_518000893">909771</advb:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopmentExpenses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12261"
      unitRef="uref_518000893">443126</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12262"
      unitRef="uref_518000893">1024795</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12263"
      unitRef="uref_518000893">1312949</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12264"
      unitRef="uref_518000893">1934566</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12265"
      unitRef="uref_518000893">-1312949</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12266"
      unitRef="uref_518000893">-1934566</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12267"
      unitRef="uref_518000893">457</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12268"
      unitRef="uref_518000893">24915</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <advb:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet
      contextRef="cref_1268430831"
      decimals="0"
      id="fc_450690150"
      unitRef="uref_518000893">235428</advb:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet>
    <advb:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet
      contextRef="cref_1127853967"
      decimals="0"
      id="fc_1998637071"
      unitRef="uref_518000893">-262848</advb:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet>
    <advb:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeNet
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12271"
      unitRef="uref_518000893">235885</advb:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeNet>
    <advb:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeNet
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12272"
      unitRef="uref_518000893">-237933</advb:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeNet>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12273"
      unitRef="uref_518000893">-1077064</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12274"
      unitRef="uref_518000893">-2172499</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <advb:DiscontinuedOperationGainLossIncurredInDiscontinuedOperations
      contextRef="cref_1268430831"
      decimals="0"
      id="fc_1528334710"
      unitRef="uref_518000893">-1077064</advb:DiscontinuedOperationGainLossIncurredInDiscontinuedOperations>
    <advb:DiscontinuedOperationGainLossIncurredInDiscontinuedOperations
      contextRef="cref_1127853967"
      decimals="0"
      id="fc_145563474"
      unitRef="uref_518000893">-2172499</advb:DiscontinuedOperationGainLossIncurredInDiscontinuedOperations>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12277"
      unitRef="uref_518000893">14015417</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12278"
      unitRef="uref_518000893">12938353</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12279"
      unitRef="uref_518000893">-2172499</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="cref_1268430831" id="ixv-8545">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;6.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS, NET&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Prepaid expenses and other current assets consisted of the following:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;As of &lt;br/&gt; June 30, &lt;br/&gt; 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;As of&lt;br/&gt; June 30, &lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Other receivables&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;490,000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_521368573;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Amount due from former subsidiaries&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;15,032,243&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1368213769;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Advances to suppliers&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1871852015;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;Prepayment&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_965959833;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,837,705&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total prepaid expenses and other current assets&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;15,524,243&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,837,705&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Less: Allowance for expected credit losses&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(2,160,266&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1375650588;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;Total prepaid expenses and other current assets, net&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;13,363,977&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;1,837,705&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; &lt;span style="font-weight: bold;"&gt;Amounts due from former subsidiaries&lt;/span&gt;. Following the dispositions of its former subsidiaries, amounts previously recorded as intercompany receivables became receivables from the former subsidiaries. As of June 30, 2026, these receivables comprised $8,602,603 due from Advanced Biomed Inc. (Taiwan), $3,134,595 due from Advanced Biomed HK Limited and $3,295,045 due from Shanghai Sglcell Biotech Co., Ltd. After an allowance for expected credit losses of $2,072,417, the net amount due from former subsidiaries was $12,959,826. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Movement of allowance for expected credit losses was shown below:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;As of&lt;br/&gt;  June 30, &lt;br/&gt; 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;As of &lt;br/&gt; June 30, &lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Beginning balance, July 1&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_865206575;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1993217282;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Provision for allowance for expected credit losses for the year&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2,918,909&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_708193469;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Written off during the year&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(758,643&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1390680715;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Ending balance, June 30&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;2,160,266&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1426344310;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="cref_1268430831" id="ixv-8553">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Prepaid expenses and other current assets consisted of the following:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;As of &lt;br/&gt; June 30, &lt;br/&gt; 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;As of&lt;br/&gt; June 30, &lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Other receivables&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;490,000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_521368573;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Amount due from former subsidiaries&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;15,032,243&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1368213769;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Advances to suppliers&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1871852015;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;Prepayment&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_965959833;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,837,705&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total prepaid expenses and other current assets&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;15,524,243&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,837,705&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Less: Allowance for expected credit losses&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(2,160,266&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1375650588;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;Total prepaid expenses and other current assets, net&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;13,363,977&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;1,837,705&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="cref_1380723918"
      decimals="0"
      id="fc_238682147"
      unitRef="uref_518000893">490000</us-gaap:OtherPrepaidExpenseCurrent>
    <advb:AmountDueFromFormerSubsidiaries
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12281"
      unitRef="uref_518000893">15032243</advb:AmountDueFromFormerSubsidiaries>
    <us-gaap:Supplies
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12282"
      unitRef="uref_518000893">2000</us-gaap:Supplies>
    <advb:PrepaymentCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="fc_1391001106"
      unitRef="uref_518000893">1837705</advb:PrepaymentCurrent>
    <advb:PrepaidExpenseAndOtherCurrentAssetsGross
      contextRef="cref_1380723918"
      decimals="0"
      id="fc_1578031840"
      unitRef="uref_518000893">15524243</advb:PrepaidExpenseAndOtherCurrentAssetsGross>
    <advb:PrepaidExpenseAndOtherCurrentAssetsGross
      contextRef="cref_1096537008"
      decimals="0"
      id="fc_2016378566"
      unitRef="uref_518000893">1837705</advb:PrepaidExpenseAndOtherCurrentAssetsGross>
    <us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12286"
      unitRef="uref_518000893">2160266</us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_1380723918"
      decimals="0"
      id="fc_42708109"
      unitRef="uref_518000893">13363977</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="fc_1771406522"
      unitRef="uref_518000893">1837705</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherReceivablesGrossCurrent
      contextRef="cref_1161182051"
      decimals="0"
      id="fc_1161182051"
      unitRef="uref_518000893">8602603</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:OtherReceivablesGrossCurrent
      contextRef="cref_934092959"
      decimals="0"
      id="fc_934092959"
      unitRef="uref_518000893">3134595</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:OtherReceivablesGrossCurrent
      contextRef="cref_98957588"
      decimals="0"
      id="fc_98957588"
      unitRef="uref_518000893">3295045</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent
      contextRef="cref_651681905"
      decimals="0"
      id="fc_1793639953"
      unitRef="uref_518000893">2072417</us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="cref_651681905"
      decimals="0"
      id="fc_651681905"
      unitRef="uref_518000893">12959826</us-gaap:OtherReceivablesNetCurrent>
    <advb:AllowanceForExpectedCreditLossesTableTextBlock contextRef="cref_1268430831" id="ixv-8651">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Movement of allowance for expected credit losses was shown below:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;As of&lt;br/&gt;  June 30, &lt;br/&gt; 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;As of &lt;br/&gt; June 30, &lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Beginning balance, July 1&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_865206575;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1993217282;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Provision for allowance for expected credit losses for the year&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2,918,909&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_708193469;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Written off during the year&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(758,643&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1390680715;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Ending balance, June 30&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;2,160,266&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1426344310;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</advb:AllowanceForExpectedCreditLossesTableTextBlock>
    <advb:ProvisionForAllowanceForExpectedCreditLosses
      contextRef="cref_1268430831"
      decimals="0"
      id="fc_291516283"
      unitRef="uref_518000893">2918909</advb:ProvisionForAllowanceForExpectedCreditLosses>
    <advb:AllowanceForExpectedCreditLossesWriteoff
      contextRef="cref_1268430831"
      decimals="0"
      id="fc_1414208642"
      unitRef="uref_518000893">-758643</advb:AllowanceForExpectedCreditLossesWriteoff>
    <advb:AllowanceForExpectedCreditLosses
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12296"
      unitRef="uref_518000893">2160266</advb:AllowanceForExpectedCreditLosses>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="cref_1268430831" id="ixv-8714">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;7.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;ACCOUNTS PAYABLE, ACCRUALS AND OTHER CURRENT LIABILITIES&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Accounts payable, accruals and other current liabilities consisted of the following:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;As of &lt;br/&gt; June 30,&lt;br/&gt;  2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;As of &lt;br/&gt; June 30, &lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Accrued payroll&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;142,147&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;85,743&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Other payables&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;21,953&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;246,988&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Amount due to related parties &#x2013; current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,078,215&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2062229985;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Accrued Liabilities&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;231,674&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;448,100&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;Total Accounts payable, accruals, and other current liabilities&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;1,473,989&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;780,831&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="cref_1268430831" id="ixv-8722">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Accounts payable, accruals and other current liabilities consisted of the following:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;As of &lt;br/&gt; June 30,&lt;br/&gt;  2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;As of &lt;br/&gt; June 30, &lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Accrued payroll&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;142,147&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;85,743&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Other payables&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;21,953&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;246,988&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Amount due to related parties &#x2013; current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,078,215&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2062229985;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Accrued Liabilities&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;231,674&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;448,100&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;Total Accounts payable, accruals, and other current liabilities&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;1,473,989&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;780,831&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="cref_1380723918"
      decimals="0"
      id="fc_75394894"
      unitRef="uref_518000893">142147</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="fc_969032629"
      unitRef="uref_518000893">85743</us-gaap:AccruedPayrollTaxesCurrent>
    <advb:OtherPayablesCurrent
      contextRef="cref_1380723918"
      decimals="0"
      id="fc_760550558"
      unitRef="uref_518000893">21953</advb:OtherPayablesCurrent>
    <advb:OtherPayablesCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="fc_1433738526"
      unitRef="uref_518000893">246988</advb:OtherPayablesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12301"
      unitRef="uref_518000893">1078215</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12302"
      unitRef="uref_518000893">231674</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12303"
      unitRef="uref_518000893">448100</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12304"
      unitRef="uref_518000893">1473989</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12305"
      unitRef="uref_518000893">780831</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="cref_1268430831" id="ixv-8797">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;8.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;EQUITY&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Common Stock&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0;"&gt; The Company is authorized to issue common stock with a par value of $0.001 per share. The Company has one class of common stock, which is classified as permanent equity. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; On October 15, 2024, the Company effected a 1-for-5 reverse stock split. On February 20, 2026, the Company effected a 1-for-20 reverse stock split of its issued and outstanding common stock. All share and per-share amounts presented in the accompanying consolidated financial statements and notes have been retrospectively adjusted to reflect the stock splits for all periods presented, as applicable. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Initial Public Offering&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; On March 7, 2025, the Company completed its initial public offering, pursuant to which the Company issued 1,640,000 shares of common stock at an offering price of $4.00 per share, before giving effect to the subsequent 1-for-20 reverse stock split. Those shares represent 82,000 shares after giving retroactive effect to the February 2026 reverse stock split. The Company received gross proceeds of $6.56 million before deducting underwriting discounts and offering expenses. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Private Placement&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; During the year ended June 30, 2026, the Company issued 200,000 shares of common stock in a private placement for aggregate proceeds of $248,000. The Company recorded $200 in common stock and $247,800 in additional paid-in capital in connection with the issuance. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Shares Issued for Commitment Fee&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; During the year ended June 30, 2026, the Company issued 82,536 shares of common stock, after giving retroactive effect to the February 2026 reverse stock split, as a commitment fee in connection with an equity line of credit arrangement. The shares had an aggregate value of $500,000, of which $83 was recorded in common stock and $499,917 in additional paid-in capital. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Fractional Share Adjustments&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; In connection with the February 2026 reverse stock split, the Company issued 17,597 shares as a result of fractional share adjustments. As presented in the accompanying consolidated statement of changes in stockholders&#x2019; equity, the issuance increased common stock by $17 and decreased additional paid-in capital by $17, with no effect on total stockholders&#x2019; equity. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Shares Issued for acquisition of Acellent and stock-based compensation&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; During the year ended June 30, 2026, the Company issued 270,000 shares of common stock as a consideration for acquiring the entire issued shares of Acellent to an independent individual and as compensation for the seller to accept as a position of director and CEO of the Company. As a result, the acquired merely cash of $12,891 with $270 as common stock and $12,621 as additional paid-in capital, respectively, was recognized as acquisition of subsidiary. While the remaining fair value of the issue common stock of $1,734,009 was recognized stock-based compensation by increasing the additional paid-in capital. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1380723918"
      decimals="3"
      id="ixv-12306"
      unitRef="uref_1427765276">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="cref_629018526" id="ixv-12307">1-for-5</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="cref_1367130439" id="ixv-12308">1-for-20</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_838649397"
      decimals="0"
      id="ixv-12309"
      unitRef="uref_1493501123">1640000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="cref_1427765276"
      decimals="2"
      id="ixv-12310"
      unitRef="uref_1427765276">4</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="cref_838649397" id="ixv-12311">1-for-20</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="cref_1925713941"
      decimals="0"
      id="fc_1925713941"
      unitRef="uref_1493501123">82000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="cref_838649397"
      decimals="-4"
      id="ixv-12313"
      unitRef="uref_518000893">6560000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_776183407"
      decimals="0"
      id="fc_459087403"
      unitRef="uref_1493501123">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="cref_776183407"
      decimals="0"
      id="fc_776183407"
      unitRef="uref_518000893">248000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="cref_805845135"
      decimals="0"
      id="fc_805845135"
      unitRef="uref_518000893">200</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="cref_1796841557"
      decimals="0"
      id="fc_1796841557"
      unitRef="uref_518000893">247800</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="cref_2117020605"
      decimals="0"
      id="ixv-12318"
      unitRef="uref_1493501123">82536</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_999016331"
      decimals="0"
      id="ixv-12319"
      unitRef="uref_518000893">500000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_2117020605"
      decimals="0"
      id="ixv-12320"
      unitRef="uref_518000893">83</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_332577736"
      decimals="0"
      id="ixv-12321"
      unitRef="uref_518000893">499917</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="cref_1720826237"
      decimals="0"
      id="ixv-12322"
      unitRef="uref_1493501123">17597</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_1720826237"
      decimals="0"
      id="ixv-12323"
      unitRef="uref_518000893">17</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_881634151"
      decimals="0"
      id="ixv-12324"
      unitRef="uref_518000893">-17</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_400658640"
      decimals="0"
      id="ixv-12325"
      unitRef="uref_1493501123">270000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_1684648503"
      decimals="0"
      id="ixv-12326"
      unitRef="uref_518000893">12891</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_400658640"
      decimals="0"
      id="ixv-12327"
      unitRef="uref_518000893">270</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_753226158"
      decimals="0"
      id="ixv-12328"
      unitRef="uref_518000893">12621</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1684648503"
      decimals="0"
      id="ixv-12329"
      unitRef="uref_518000893">1734009</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="cref_1268430831" id="ixv-8831">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;9.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;INCOME TAXES&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt; Advanced Biomed Inc. is incorporated in the State of Nevada and is subject to U.S. federal income tax at a statutory rate of 21%. Nevada does not impose a state corporate income tax. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Acellent Technologies (Hong Kong) Co. Limited, which was acquired during the year ended June 30, 2026, is subject to Hong Kong profits tax. Under Hong Kong&#x2019;s two-tiered profits tax regime, the first HK$2 million of a corporation&#x2019;s assessable profits is taxed at 8.25%, and assessable profits in excess of HK$2 million are taxed at 16.5%. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;       &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; For the year ended June 30, 2026, the Company recognized a deferred income tax benefit of $1,205 from continuing operations related to the recognition of a deferred tax asset for tax loss carryforwards of Acellent. The related deferred tax asset was $1,204 as of June 30, 2026. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The components of income tax benefit from continuing operations were as follows:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;For the years ended &lt;br/&gt; June 30&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify;"&gt;Current income tax expense&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_533274868;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_519175881;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="width: 76%; text-align: justify; padding-bottom: 1.5pt;"&gt;Deferred income tax benefit - Hong Kong income tax&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;(1,205&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1377035759;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt;"&gt;Total income tax benefit from continuing operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(1,205&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_99184308;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The following table reconciles income tax benefit computed at the U.S. federal statutory tax rate to income tax benefit from continuing operations:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;For the years ended &lt;br/&gt; June 30&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;%&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;%&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Tax at U.S. federal statutory rate&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;21.00&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;21.00&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;State and local income taxes, net of federal effect&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_995735450;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_558512107;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Foreign tax effects&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(0.03&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1323830959;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Changes in valuation allowance&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(13.46&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(21.00&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Nondeductible expenses&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(7.49&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1459257994;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt;"&gt;Effective tax rate&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;0.02&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;0.00&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The components of deferred tax assets were as follows:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;As of &lt;br/&gt; June 30, &lt;br/&gt; 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;As of &lt;br/&gt; June 30, &lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: justify;"&gt;Net operating loss carryforwards&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;725,157&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;494,013&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;Allowance for expected credit losses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;612,971&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1798789769;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: justify;"&gt;Gross deferred tax assets&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,338,128&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;494,013&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;Less: valuation allowance&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(1,336,924&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(494,013&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt;"&gt;Deferred tax assets, net&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;1,204&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1825277270;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;       &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The Company recognized a deferred income tax benefit of $1,205 for the year ended June 30, 2026 related to a tax loss carryforward of Acellent. The corresponding deferred tax asset balance was $1,204 as of June 30, 2026. The difference between the benefit recognized during the year and the year-end asset reflects foreign currency translation. The Company&#x2019;s U.S. deferred tax assets were fully offset by a valuation allowance as of June 30, 2026 and 2025. The net operating loss carry forwards for U.S. federal tax and Hong Kong tax purposes are available for carry forward indefinitely for use in offsetting taxable income. The U.S. federal net operating loss carry forward offset is limited to up to 80% of the taxable income. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; For continuing operations, as of June 30, 2026 and 2025, the Company had total net operating loss carry forwards of approximately $3,561,863 and $2,352,444, respectively, which consists of Hong Kong net operating losses of $14,597 and &lt;span style="-sec-ix-hidden:fc_1089681296;"&gt;nil&lt;/span&gt;, respectively and US net operating loss carry forwards of $3,447,396 and $2,352,444, respectively. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; For discontinued operations, as of June 30, 2026 and 2025, the Company had total net operating loss carry forwards of approximately &lt;span style="-sec-ix-hidden:fc_519963710;"&gt;nil&lt;/span&gt; and $10,815,272, respectively, which consists of Taiwan net operating loss carry forwards &lt;span style="-sec-ix-hidden:fc_1568172215;"&gt;nil&lt;/span&gt; and $5,824,336, China net operating loss carry forwards of &lt;span style="-sec-ix-hidden:fc_717167906;"&gt;nil&lt;/span&gt;&#160;and $4,896,250 and Hong Kong net operating loss carry forwards of &lt;span style="-sec-ix-hidden:fc_1539137384;"&gt;nil&lt;/span&gt; and $94,686, respectively.&#160; &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="cref_1556537373"
      decimals="2"
      id="ixv-12330"
      unitRef="uref_1766841203">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="cref_1268430831"
      decimals="-6"
      id="ixv-12331"
      unitRef="uref_205481031">2000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="cref_615613204"
      decimals="4"
      id="fc_112773823"
      unitRef="uref_1766841203">0.0825</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="cref_615613204"
      decimals="-6"
      id="ixv-12333"
      unitRef="uref_205481031">2000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="cref_615613204"
      decimals="3"
      id="ixv-12334"
      unitRef="uref_1766841203">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12335"
      unitRef="uref_518000893">-1205</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12336"
      unitRef="uref_518000893">1204</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="cref_1268430831" id="ixv-8852">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The components of income tax benefit from continuing operations were as follows:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;For the years ended &lt;br/&gt; June 30&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: justify;"&gt;Current income tax expense&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_533274868;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_519175881;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="width: 76%; text-align: justify; padding-bottom: 1.5pt;"&gt;Deferred income tax benefit - Hong Kong income tax&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;(1,205&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1377035759;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt;"&gt;Total income tax benefit from continuing operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(1,205&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_99184308;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12337"
      unitRef="uref_518000893">-1205</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12338"
      unitRef="uref_518000893">-1205</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="cref_1268430831" id="ixv-8914">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The following table reconciles income tax benefit computed at the U.S. federal statutory tax rate to income tax benefit from continuing operations:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;For the years ended &lt;br/&gt; June 30&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;%&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;%&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Tax at U.S. federal statutory rate&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;21.00&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;21.00&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;State and local income taxes, net of federal effect&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_995735450;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_558512107;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Foreign tax effects&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(0.03&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1323830959;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Changes in valuation allowance&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(13.46&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(21.00&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Nondeductible expenses&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(7.49&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1459257994;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt;"&gt;Effective tax rate&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;0.02&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;0.00&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="cref_1268430831"
      decimals="4"
      id="fc_983477486"
      unitRef="uref_1766841203">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="cref_1127853967"
      decimals="4"
      id="ixv-12340"
      unitRef="uref_1766841203">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="cref_1268430831"
      decimals="4"
      id="fc_1473286141"
      unitRef="uref_1766841203">-0.0003</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="cref_1268430831"
      decimals="4"
      id="ixv-12342"
      unitRef="uref_1766841203">-0.1346</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="cref_1127853967"
      decimals="4"
      id="ixv-12343"
      unitRef="uref_1766841203">-0.21</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="cref_1268430831"
      decimals="4"
      id="ixv-12344"
      unitRef="uref_1766841203">-0.0749</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="cref_1268430831"
      decimals="4"
      id="ixv-12345"
      unitRef="uref_1766841203">0.0002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="cref_1127853967"
      decimals="4"
      id="ixv-12346"
      unitRef="uref_1766841203">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="cref_1268430831" id="ixv-9006">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The components of deferred tax assets were as follows:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;As of &lt;br/&gt; June 30, &lt;br/&gt; 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;As of &lt;br/&gt; June 30, &lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: justify;"&gt;Net operating loss carryforwards&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;725,157&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;494,013&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify;"&gt;Allowance for expected credit losses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;612,971&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1798789769;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: justify;"&gt;Gross deferred tax assets&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,338,128&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;494,013&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;Less: valuation allowance&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(1,336,924&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(494,013&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt;"&gt;Deferred tax assets, net&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;1,204&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1825277270;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12347"
      unitRef="uref_518000893">725157</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12348"
      unitRef="uref_518000893">494013</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <advb:DeferredTaxAssetsAllowanceForExpectedCreditLosses
      contextRef="cref_1380723918"
      decimals="0"
      id="fc_1439324510"
      unitRef="uref_518000893">612971</advb:DeferredTaxAssetsAllowanceForExpectedCreditLosses>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12350"
      unitRef="uref_518000893">1338128</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12351"
      unitRef="uref_518000893">494013</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12352"
      unitRef="uref_518000893">1336924</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="cref_1096537008"
      decimals="0"
      id="ixv-12353"
      unitRef="uref_518000893">494013</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12354"
      unitRef="uref_518000893">1204</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12355"
      unitRef="uref_518000893">-1205</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="cref_1380723918"
      decimals="0"
      id="ixv-12356"
      unitRef="uref_518000893">1204</us-gaap:DeferredTaxAssetsNet>
    <advb:NetOperatingLossCarryForwardOffset
      contextRef="cref_1268430831"
      decimals="2"
      id="ixv-12357"
      unitRef="uref_1766841203">0.80</advb:NetOperatingLossCarryForwardOffset>
    <us-gaap:OperatingLossCarryforwards
      contextRef="cref_695989797"
      decimals="0"
      id="ixv-12358"
      unitRef="uref_518000893">3561863</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="cref_708356424"
      decimals="0"
      id="ixv-12359"
      unitRef="uref_518000893">2352444</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="cref_1373556371"
      decimals="0"
      id="ixv-12360"
      unitRef="uref_518000893">14597</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="cref_1670724461"
      decimals="0"
      id="ixv-12361"
      unitRef="uref_518000893">3447396</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="cref_607253543"
      decimals="0"
      id="ixv-12362"
      unitRef="uref_518000893">2352444</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="cref_305121392"
      decimals="0"
      id="ixv-12363"
      unitRef="uref_518000893">10815272</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="cref_2033103817"
      decimals="0"
      id="ixv-12364"
      unitRef="uref_518000893">5824336</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="cref_372109222"
      decimals="0"
      id="ixv-12365"
      unitRef="uref_518000893">4896250</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="cref_1071870216"
      decimals="0"
      id="ixv-12366"
      unitRef="uref_518000893">94686</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="cref_1268430831" id="ixv-9102">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;10.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;STOCK INCENTIVE PLAN&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Effective from March 30, 2023, the Stock Incentive Plan (the &#x201c;2023 Plan&#x201d;) was approved by the Company&#x2019;s Board of Directors. Under the 2023 Plan, the Board of Directors may grant options or purchase rights to purchase common stock to officers, employees, and other persons who provide services to the Company or any related company. The participants to whom awards are granted, the type of awards granted, the number of shares covered for each award, and the purchase or exercise price, conditions and other terms of each award are determined by the Board of Directors, except that the term of the options shall not exceed 10 years. A total of 15 million shares of the Company&#x2019;s common stock are subject to the 2023 Plan and maybe either a qualified or non-qualified stock option. The shares issued for the 2023 Plan may be either treasury or authorized and unissued shares. As of the date of this report, the Company has granted &lt;span style="-sec-ix-hidden:fc_1527746651;"&gt;no&lt;/span&gt; stock options to purchase any shares of the common stock under the 2023 Plan. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="cref_1042470024" id="ixv-12367">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="cref_1493501123"
      decimals="-6"
      id="ixv-12368"
      unitRef="uref_1493501123">15000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="cref_1268430831" id="ixv-9113">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;11.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;RELATED PARTY TRANSACTIONS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The Company had &lt;span style="-sec-ix-hidden:fc_516370733;"&gt;&lt;span style="-sec-ix-hidden:fc_91068169;"&gt;no&lt;/span&gt;&lt;/span&gt; related-party transactions during the years ended June 30, 2026 and 2025, while the financial statements reflect advances received from related parties during both years. The Company has balances with certain stockholders, officers, directors and entities related to them as of June 30, 2026 and 2025. The relationships relevant to the periods presented are summarized below: &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr&gt;&lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 40%;"&gt;&lt;span style="font-weight: bold;"&gt;Related party &lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 2%;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 58%; font-size: 10pt; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;Relationship to the Company&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"&gt;Xiaomin Chen&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;Chief Executive Officer and Chairman of the Board; Stockholder&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: White;"&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;Hung To Pau, Ph.D.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;Stockholder&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;Jie Wang&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;Stockholder of the Company&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: White;"&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;Well Fancy Development Ltd.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;Hung To Pau is the director and stockholder of the entity&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The balances with related parties were as follows:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;Amounts due to related parties &#x2014; stockholders&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold;"&gt;Related party&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;As of &lt;br/&gt;     June 30, &lt;br/&gt;     2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;As of &lt;br/&gt;     June 30,&lt;br/&gt;     2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"&gt;Xiaomin Chen&lt;/p&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;36,000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_748908903;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Jie Wang&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;607,014&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_562830761;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;643,014&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1384483165;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;       &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;Amounts due to related parties &#x2014; related corporations, current&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;span style="font-weight: bold;"&gt;Related party&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;As of &lt;br/&gt;     June 30, &lt;br/&gt;     2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;As of &lt;br/&gt;     June 30, &lt;br/&gt;     2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt;"&gt;Well Fancy Development Ltd.&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;435,201&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1006299734;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;435,201&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_709321675;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;Amounts due to related parties &#x2014; related corporations, non-current&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;span style="font-weight: bold;"&gt;Related party&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;As of &lt;br/&gt;     June 30, &lt;br/&gt;     2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;As of &lt;br/&gt;     June 30, &lt;br/&gt;     2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt;"&gt;Well Fancy Development Ltd.&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_78357966;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;69,975&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold;"&gt;Total&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_92680800;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;69,975&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Note:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The amounts due to related parties are advances from related parties for payment of expenses of the Company. The balances are interest-free, unsecured and repayable on demand other than the loan balance due to Mr. Jie Wang, in which the loan was bearing an interest rate of 10% per annum, repayable within one year and unsecured. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="cref_1268430831" id="ixv-12369">The relationships relevant to the periods presented are summarized below:&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr&gt;&lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 40%;"&gt;&lt;span style="font-weight: bold;"&gt;Related party &lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 2%;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 58%; font-size: 10pt; text-align: center;"&gt;&lt;span style="font-size: 10pt;"&gt;Relationship to the Company&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"&gt;Xiaomin Chen&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;Chief Executive Officer and Chairman of the Board; Stockholder&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: White;"&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;Hung To Pau, Ph.D.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;Stockholder&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;Jie Wang&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;Stockholder of the Company&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: White;"&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;Well Fancy Development Ltd.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;Hung To Pau is the director and stockholder of the entity&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="cref_2097405023" id="ixv-12370">Chief Executive Officer and Chairman of the Board; Stockholder</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="cref_347602649" id="ixv-9144">Stockholder</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="cref_1035987879" id="ixv-9151">Stockholder of the Company</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="cref_1555499812" id="ixv-9158">Hung To Pau is the director and stockholder of the entity</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <advb:ScheduleOfTransactionWithThesePartiesTableTextBlock contextRef="cref_1268430831" id="ixv-9161">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The balances with related parties were as follows:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;Amounts due to related parties &#x2014; stockholders&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold;"&gt;Related party&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;As of &lt;br/&gt;     June 30, &lt;br/&gt;     2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;As of &lt;br/&gt;     June 30,&lt;br/&gt;     2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"&gt;Xiaomin Chen&lt;/p&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;36,000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_748908903;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Jie Wang&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;607,014&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_562830761;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;643,014&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1384483165;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;Amounts due to related parties &#x2014; related corporations, current&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;span style="font-weight: bold;"&gt;Related party&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;As of &lt;br/&gt;     June 30, &lt;br/&gt;     2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;As of &lt;br/&gt;     June 30, &lt;br/&gt;     2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt;"&gt;Well Fancy Development Ltd.&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;435,201&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1006299734;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;435,201&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_709321675;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;Amounts due to related parties &#x2014; related corporations, non-current&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;span style="font-weight: bold;"&gt;Related party&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;As of &lt;br/&gt;     June 30, &lt;br/&gt;     2026&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;As of &lt;br/&gt;     June 30, &lt;br/&gt;     2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt;"&gt;Well Fancy Development Ltd.&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_78357966;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;69,975&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold;"&gt;Total&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_92680800;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;69,975&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</advb:ScheduleOfTransactionWithThesePartiesTableTextBlock>
    <us-gaap:OtherLiabilities
      contextRef="cref_1784635127"
      decimals="0"
      id="ixv-12371"
      unitRef="uref_518000893">36000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="cref_1519822248"
      decimals="0"
      id="fc_1519822248"
      unitRef="uref_518000893">607014</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="cref_1398217206"
      decimals="0"
      id="fc_1398217206"
      unitRef="uref_518000893">643014</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="cref_481337955"
      decimals="0"
      id="ixv-12374"
      unitRef="uref_518000893">435201</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="cref_1973210640"
      decimals="0"
      id="ixv-12375"
      unitRef="uref_518000893">435201</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="cref_554179130"
      decimals="0"
      id="ixv-12376"
      unitRef="uref_518000893">69975</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="cref_1226777713"
      decimals="0"
      id="ixv-12377"
      unitRef="uref_518000893">69975</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="cref_1766841203"
      decimals="2"
      id="ixv-12378"
      unitRef="uref_1766841203">0.10</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="cref_1268430831" id="ixv-9381">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;12.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;SEGMENT INFORMATION&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The Company operates and manages its continuing operations as a single reportable segment, which is consistent with how the Chief Operating Decision Maker (&#x201c;CODM&#x201d;), the &lt;span style="-sec-ix-hidden:fc_993672847;"&gt;Chief Executive Officer&lt;/span&gt;, makes operating decisions and allocates resources. The CODM assesses performance and results of operations at the Company level. The Company&#x2019;s operations are centralized and integrated, with financial results reviewed and managed on a consolidated basis.&#160;Accordingly, management has determined that the Company has one reportable segment under ASC Topic 280, Segment Reporting. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Measure of Segment Profit or Loss&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The CODM assesses performance for the segment and decides how to allocate resources by regularly reviewing the net loss from continuing operations from the statement of operations, after taking into account the Company&#x2019;s strategic priorities, its cash balance, and its expected use of cash. The following table presents the significant income and expense categories in the Company&#x2019;s single operating segment:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;For the &lt;br/&gt; years ended &lt;br/&gt; June 30, &lt;br/&gt; 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;For the &lt;br/&gt; years ended &lt;br/&gt; June 30, &lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%;"&gt;Revenue&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;127,637&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1067729861;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Stock-based compensation&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,734,009&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1668669101;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;General and administrative expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(4,627,170&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,086,470&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Other items, net&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(27,734&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1535481324;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt;"&gt;Loss from continuing operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(6,261,276&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(1,086,470&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Other items from continuing operations, net, for year ended June 30, 2026 consist of the $7,014 of interest expense and $21,925 of other expense, net, plus a $1,205 income tax benefit. &lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription contextRef="cref_1268430831" id="ixv-9390">The Company operates and manages its continuing operations as a single reportable segment, which is consistent with how the Chief Operating Decision Maker (&#x201c;CODM&#x201d;), the Chief Executive Officer, makes operating decisions and allocates resources.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:NumberOfReportableSegments
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12379"
      unitRef="uref_345177085">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="cref_1268430831" id="ixv-12380">The following table presents the significant income and expense categories in the Company&#x2019;s single operating segment:&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;For the &lt;br/&gt; years ended &lt;br/&gt; June 30, &lt;br/&gt; 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;For the &lt;br/&gt; years ended &lt;br/&gt; June 30, &lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;US$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%;"&gt;Revenue&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;127,637&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1067729861;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Stock-based compensation&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,734,009&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1668669101;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;General and administrative expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(4,627,170&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,086,470&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Other items, net&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(27,734&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1535481324;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt;"&gt;Loss from continuing operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(6,261,276&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;(1,086,470&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:Revenues
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12381"
      unitRef="uref_518000893">127637</us-gaap:Revenues>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12382"
      unitRef="uref_518000893">1734009</us-gaap:ShareBasedCompensation>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12383"
      unitRef="uref_518000893">4627170</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12384"
      unitRef="uref_518000893">1086470</us-gaap:GeneralAndAdministrativeExpense>
    <advb:OtherItemsFromContinuingOperations
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12385"
      unitRef="uref_518000893">-27734</advb:OtherItemsFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12386"
      unitRef="uref_518000893">-6261276</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="cref_1127853967"
      decimals="0"
      id="ixv-12387"
      unitRef="uref_518000893">-1086470</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="cref_1268430831"
      decimals="0"
      id="fc_1356028453"
      unitRef="uref_518000893">-7014</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12389"
      unitRef="uref_518000893">-21925</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="cref_1268430831"
      decimals="0"
      id="ixv-12390"
      unitRef="uref_518000893">-1205</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="cref_1268430831" id="ixv-9484">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;13.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;CONCENTRATIONS AND RISKS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Financial assets of the Company that are potentially subject to credit risk mainly consist of cash, other current assets and amounts due from discontinued operations.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The Company&#x2019;s cash deposits are maintained with high credit quality institutions, the composition and maturities of which are regularly monitored by management. In Hong Kong, an individual entity&#x2019;s deposit maintained at a bank is insured for a maximum of HKD800,000 (equivalent to approximately $102,000) in the event of bank failure. In the U.S., the Company may carry cash balances at financial institutions more than the federally insured limit of $250,000 per institution. As of June 30, 2026, a cash balance of $140,439 was maintained at financial institutions in Hong Kong, of which approximately $38,438 was not insured; and cash balance of $245,096 was maintained at financial institutions in the U.S., of which nil was not insured. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In terms of other current receivable and amounts due from discontinued operations, the Company maintains allowances for expected credit losses as contra accounts, as mentioned above.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Liquidity Risk&lt;/i&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company&#x2019;s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company&#x2019;s reputation.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Typically, the Company ensures that it has sufficient cash on demand to meet expected operational expenses for a period of 60 days, including the servicing of financial obligations; this excludes the potential impact of extreme circumstances that cannot reasonably be predicted, such as natural disasters. &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Foreign currency risk&lt;/i&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The company&#x2019;s exposure to the risk of changes in foreign exchange rates relates primarily to the Company&#x2019;s operating activities (when expense is denominated in a foreign currency) and the Company&#x2019;s net investments in foreign subsidiaries.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Impact of Inflation&lt;/i&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Inflation in Hong Kong has not materially affected the Company&#x2019;s profitability and operating results. However, the Company can provide no assurance that we will be unaffected by higher inflation rates in Hong Kong or globally in the future.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <advb:BankDepositInsuranceLimit
      contextRef="cref_1380723918"
      decimals="0"
      id="fc_205481031"
      unitRef="uref_205481031">800000</advb:BankDepositInsuranceLimit>
    <advb:BankDepositInsuranceLimit
      contextRef="cref_1380723918"
      decimals="0"
      id="fc_1380723918"
      unitRef="uref_518000893">102000</advb:BankDepositInsuranceLimit>
    <advb:BankDepositInsuranceLimit
      contextRef="cref_518000893"
      decimals="0"
      id="fc_1652621976"
      unitRef="uref_518000893">250000</advb:BankDepositInsuranceLimit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_1292941150"
      decimals="0"
      id="ixv-12394"
      unitRef="uref_518000893">140439</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <advb:BankDepositInsuranceLimit
      contextRef="cref_1292941150"
      decimals="0"
      id="fc_1292941150"
      unitRef="uref_518000893">38438</advb:BankDepositInsuranceLimit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_518000893"
      decimals="0"
      id="ixv-12396"
      unitRef="uref_518000893">245096</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <advb:NumberOfDaysForOperationalExpenses contextRef="cref_1268430831" id="ixv-12397">P60D</advb:NumberOfDaysForOperationalExpenses>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="cref_1268430831" id="ixv-9522">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 18.2pt;"&gt;14.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.2pt; text-align: justify; text-indent: -18.2pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Contingencies&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In the ordinary course of business, the Company may be subject to legal proceedings, claims and other matters. The Company accrues a loss contingency when a loss is probable and the amount can be reasonably estimated.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;As of June 30, 2026, the Company was not aware of any pending or threatened legal proceedings that would have a material effect on its consolidated balance sheets, results of operations or cash flows.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="cref_1268430831" id="ixv-9535">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;15.&lt;/td&gt; &lt;td style="text-align: justify;"&gt;SUBSEQUENT EVENTS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company evaluated subsequent events occurring after June 30, 2026 through October 13, 2026, the date the consolidated financial statements were issued. Except as described below, the Company identified no subsequent events requiring recognition or disclosure in the consolidated financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Termination of Equity Line of Credit&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;On July 14, 2026, the Company delivered notice to terminate its equity line of credit arrangement. The termination became effective on July 21, 2026. As of the date of the notice, there were no outstanding advance notices, and the Company had satisfied all amounts owed under the arrangement, including the issuance of the commitment fee shares.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#fc_1013319968"
          xlink:label="fc_1013319968"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_118352444"
          xlink:label="fc_118352444"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1344104536"
          xlink:label="fc_1344104536"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1427537372"
          xlink:label="fc_1427537372"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1985688321"
          xlink:label="fc_1985688321"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1808618487"
          xlink:label="fc_1808618487"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_554093189"
          xlink:label="fc_554093189"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_639943382"
          xlink:label="fc_639943382"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1857452080"
          xlink:label="fc_1857452080"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_79949418"
          xlink:label="fc_79949418"
          xlink:type="locator"/>
        <link:footnote id="fref_1853409698" xlink:label="fref_1853409698" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Giving retroactive effect to the 1-for-20 reverse share split effected on February 20, 2026.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1013319968"
          xlink:to="fref_1853409698"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_118352444"
          xlink:to="fref_1853409698"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1344104536"
          xlink:to="fref_1853409698"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1427537372"
          xlink:to="fref_1853409698"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1985688321"
          xlink:to="fref_1853409698"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1808618487"
          xlink:to="fref_1853409698"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_554093189"
          xlink:to="fref_1853409698"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_639943382"
          xlink:to="fref_1853409698"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1857452080"
          xlink:to="fref_1853409698"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_79949418"
          xlink:to="fref_1853409698"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_2117807913"
          xlink:label="fc_2117807913"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1630484428"
          xlink:label="fc_1630484428"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_250126196"
          xlink:label="fc_250126196"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_370814422"
          xlink:label="fc_370814422"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_900194652"
          xlink:label="fc_900194652"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_23137350"
          xlink:label="fc_23137350"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1167701535"
          xlink:label="fc_1167701535"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1921281851"
          xlink:label="fc_1921281851"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_776335972"
          xlink:label="fc_776335972"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1324410395"
          xlink:label="fc_1324410395"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_24468988"
          xlink:label="fc_24468988"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_307002805"
          xlink:label="fc_307002805"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_726916121"
          xlink:label="fc_726916121"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1295661221"
          xlink:label="fc_1295661221"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2080613918"
          xlink:label="fc_2080613918"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1893897237"
          xlink:label="fc_1893897237"
          xlink:type="locator"/>
        <link:footnote id="fref_886716130" xlink:label="fref_886716130" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Giving retroactive effect to the 1-for-20 reverse stock split effected on February 20, 2026.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2117807913"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1630484428"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_250126196"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_370814422"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_900194652"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_23137350"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1167701535"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1921281851"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_776335972"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1324410395"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_24468988"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_307002805"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_726916121"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1295661221"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2080613918"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1893897237"
          xlink:to="fref_886716130"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_1515466520"
          xlink:label="fc_1515466520"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_876291995"
          xlink:label="fc_876291995"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1430973038"
          xlink:label="fc_1430973038"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_785858763"
          xlink:label="fc_785858763"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_9630985"
          xlink:label="fc_9630985"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1242503141"
          xlink:label="fc_1242503141"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1377638562"
          xlink:label="fc_1377638562"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1609136595"
          xlink:label="fc_1609136595"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_770078133"
          xlink:label="fc_770078133"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_589906515"
          xlink:label="fc_589906515"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_362126174"
          xlink:label="fc_362126174"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2016794188"
          xlink:label="fc_2016794188"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_71328825"
          xlink:label="fc_71328825"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_969532781"
          xlink:label="fc_969532781"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_277234472"
          xlink:label="fc_277234472"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1923676656"
          xlink:label="fc_1923676656"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1013726955"
          xlink:label="fc_1013726955"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1884897091"
          xlink:label="fc_1884897091"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2024752313"
          xlink:label="fc_2024752313"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_103096211"
          xlink:label="fc_103096211"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1420963489"
          xlink:label="fc_1420963489"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1697903215"
          xlink:label="fc_1697903215"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1559650067"
          xlink:label="fc_1559650067"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1612819270"
          xlink:label="fc_1612819270"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1849258122"
          xlink:label="fc_1849258122"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1527988905"
          xlink:label="fc_1527988905"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_387718152"
          xlink:label="fc_387718152"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1956081101"
          xlink:label="fc_1956081101"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_628131206"
          xlink:label="fc_628131206"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1743990980"
          xlink:label="fc_1743990980"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_207845589"
          xlink:label="fc_207845589"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1526602125"
          xlink:label="fc_1526602125"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1311257128"
          xlink:label="fc_1311257128"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1081343444"
          xlink:label="fc_1081343444"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_266513493"
          xlink:label="fc_266513493"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_370992816"
          xlink:label="fc_370992816"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1749169838"
          xlink:label="fc_1749169838"
          xlink:type="locator"/>
        <link:footnote id="fref_1604323966" xlink:label="fref_1604323966" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Giving retroactive effect to the 1-for-20 reverse stock split effected on February 20, 2026.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1515466520"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_876291995"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1430973038"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_785858763"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_9630985"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1242503141"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1377638562"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1609136595"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_770078133"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_589906515"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_362126174"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2016794188"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_71328825"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_969532781"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_277234472"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1923676656"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1013726955"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1884897091"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2024752313"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_103096211"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1420963489"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1697903215"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1559650067"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1612819270"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1849258122"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1527988905"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_387718152"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1956081101"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_628131206"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1743990980"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_207845589"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1526602125"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1311257128"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1081343444"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_266513493"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_370992816"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1749169838"
          xlink:to="fref_1604323966"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_378644450"
          xlink:label="fc_378644450"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_197249230"
          xlink:label="fc_197249230"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1149370131"
          xlink:label="fc_1149370131"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1263417979"
          xlink:label="fc_1263417979"
          xlink:type="locator"/>
        <link:footnote id="fref_1253585425" xlink:label="fref_1253585425" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company acquired 100% of the equity interests in Acellent Technologies (Hong Kong) Co. Limited in April 2026.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_378644450"
          xlink:to="fref_1253585425"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_197249230"
          xlink:to="fref_1253585425"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1149370131"
          xlink:to="fref_1253585425"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1263417979"
          xlink:to="fref_1253585425"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_1488513075"
          xlink:label="fc_1488513075"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_492101464"
          xlink:label="fc_492101464"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1497991597"
          xlink:label="fc_1497991597"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1189438897"
          xlink:label="fc_1189438897"
          xlink:type="locator"/>
        <link:footnote id="fref_1245081769" xlink:label="fref_1245081769" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company disposed of its entire equity interest in Advanced Biomed Inc. (Taiwan) on June 30, 2026.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1488513075"
          xlink:to="fref_1245081769"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_492101464"
          xlink:to="fref_1245081769"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1497991597"
          xlink:to="fref_1245081769"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1189438897"
          xlink:to="fref_1245081769"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_1399799817"
          xlink:label="fc_1399799817"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_951683079"
          xlink:label="fc_951683079"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_372193311"
          xlink:label="fc_372193311"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_23459831"
          xlink:label="fc_23459831"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_936064758"
          xlink:label="fc_936064758"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1877900993"
          xlink:label="fc_1877900993"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_860594818"
          xlink:label="fc_860594818"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1454131596"
          xlink:label="fc_1454131596"
          xlink:type="locator"/>
        <link:footnote id="fref_2146369026" xlink:label="fref_2146369026" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company disposed of its entire equity interest in Advanced Biomed HK Limited, including its wholly owned subsidiary, Shanghai Sglcell Biotech Co., Ltd., in December 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1399799817"
          xlink:to="fref_2146369026"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_951683079"
          xlink:to="fref_2146369026"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_372193311"
          xlink:to="fref_2146369026"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_23459831"
          xlink:to="fref_2146369026"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_936064758"
          xlink:to="fref_2146369026"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1877900993"
          xlink:to="fref_2146369026"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_860594818"
          xlink:to="fref_2146369026"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1454131596"
          xlink:to="fref_2146369026"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
